University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2020

Discovering Pleiotropy Across Circulatory System Diseases And
Nervous System Disorders
Xinyuan Zhang
University of Pennsylvania

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Bioinformatics Commons

Recommended Citation
Zhang, Xinyuan, "Discovering Pleiotropy Across Circulatory System Diseases And Nervous System
Disorders" (2020). Publicly Accessible Penn Dissertations. 3970.
https://repository.upenn.edu/edissertations/3970

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3970
For more information, please contact repository@pobox.upenn.edu.

Discovering Pleiotropy Across Circulatory System Diseases And Nervous System
Disorders
Abstract
Pleiotropy is a phenomenon which describes a gene or a genetic variant that affects more than one
phenotype. This fundamental concept has been thought to play a critical role in genetics, medicine,
evolutionary biology, molecular biology, and clinical research. With the recent development in sequencing
technologies and statistical methods, pleiotropy can be characterized systematically in human genome.
Circulatory system diseases and nervous system disorders have a significant impact on mortality rates
worldwide and frequently co-occur in patients. Thus, the field would benefit greatly from the knowledge of
the underlying genetic relationship between multiple diseases in these disease categories. In this
dissertation, we aim to identify pleiotropy across a wide range of circulatory system diseases and
nervous system disorders using large-scale electronic health record-linked biobank datasets. For
common genetic variants, we applied an ensemble of methods including univariate, multivariate, and
sequential multivariate association methods to characterize pleiotropy in the UK Biobank and the
eMERGE network. Our results implicated five pleiotropic regions that help to explain the disease
relationships across these disease categories. For rare variants, we performed univariate burden and
dispersion tests using whole-exome sequencing data from the UK Biobank and characterized 143
Bonferroni significant pleiotropic genes. Our analytical framework on both common and rare genetic
variants offer novel insights into biology and provide a new perspective for studying pleiotropy in largescale biobank datasets. Besides the application of statistical methods on natural biomedical datasets, we
also conducted simulation projects investigating the impact of sample size imbalance on the
performance of the proposed statistical methods. Our simulation results can serve as a reference
guideline to assist sample size design for association studies.
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ABSTRACT
DISCOVERING PLEIOTROPY ACROSS CIRCULATORY SYSTEM DISEASES AND
NERVOUS SYSTEM DISORDERS
Xinyuan Zhang
Marylyn D. Ritchie
Pleiotropy is a phenomenon which describes a gene or a genetic variant that affects more
than one phenotype. This fundamental concept has been thought to play a critical role in
genetics, medicine, evolutionary biology, molecular biology, and clinical research. With the recent
development in sequencing technologies and statistical methods, pleiotropy can be characterized
systematically in human genome. Circulatory system diseases and nervous system disorders
have a significant impact on mortality rates worldwide and frequently co-occur in patients. Thus,
the field would benefit greatly from the knowledge of the underlying genetic relationship between
multiple diseases in these disease categories. In this dissertation, we aim to identify pleiotropy
across a wide range of circulatory system diseases and nervous system disorders using largescale electronic health record-linked biobank datasets. For common genetic variants, we applied
an ensemble of methods including univariate, multivariate, and sequential multivariate association
methods to characterize pleiotropy in the UK Biobank and the eMERGE network. Our results
implicated five pleiotropic regions that help to explain the disease relationships across these
disease categories. For rare variants, we performed univariate burden and dispersion tests using
whole-exome sequencing data from the UK Biobank and characterized 143 Bonferroni significant
pleiotropic genes. Our analytical framework on both common and rare genetic variants offer novel
insights into biology and provide a new perspective for studying pleiotropy in large-scale biobank
datasets. Besides the application of statistical methods on natural biomedical datasets, we also
conducted simulation projects investigating the impact of sample size imbalance on the
performance of the proposed statistical methods. Our simulation results can serve as a reference
guideline to assist sample size design for association studies.
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CHAPTER 1 Analytical methods to uncover pleiotropy in electronic health record
linked biobanks

1.1

Abstract
Pleiotropy, which describes a genetic variant or a gene that affects more than one trait, is an

important concept in biology. The advances in sequencing technologies and statistical methods
offer new opportunities to study pleiotropy in human genome. Many promising electronic health
record (EHR)-linked biobanks are being built to elucidate the genetic architecture of human
diseases. With effective analytical approaches being applied to data from EHR-linked biobanks,
pleiotropy in the human genome can be characterized to understand shared biology underlying
human traits. Here, we first introduce the history of pleiotropy studies in human genome. We then
review analytical methods deigned for common variants and rare variants for detecting pleiotropy.
We lastly discuss challenges and future directions in this topic.

1.2

Introduction
A genetic variant or a gene may affect multiple traits. The phenomenon, known as

pleiotropy, has had important influence on many aspects of biology1. Previous genetics studies
limited to focus on defining a single function of each gene, which works well for ubiquitously
expressed (or “housekeeping”) genes and tissue-specific (or “luxury”) genes2. However, most of
the genes in complex organisms are expressed in multiple tissues, with potential functional
variation, meaning that each gene may have different functions in each scenario2. This leads to
various forms of trait manifestations, or even may result in seemly unrelated phenotypes. A better
understanding of this inherent property of genetic material is one of the critical research
endeavors in human genetics as the field attempts to elucidate the genetic architecture for
complex traits.
1

Biomedical datasets, which link genotypic information to clinical phenotypes, provide
unprecedented opportunities to design powerful studies to understand complex traits3. The
information from the healthcare records from a healthcare system, such as the electronic health
records (EHRs), offer a systematic characterization of health and disease profile for every patientparticipant. Meanwhile, the genetic materials are being curated in a variety of aspects, including
common variants, rare variants, copy-number variations, structural variations, etc. Coupling these
resources, bioinformatics tools, and statistical methods will provide the necessary infrastructure to
assist in revealing novel biological knowledge.
In this chapter, we review the current states of statistical methods that can be applied to
identify pleiotropy in an EHR-linked biobank. Specifically, this review is focused on methods that
are designed for studies where individual-level data are available. There are a number of new
methods that focus on using genome-wide association study (GWAS) summary statistics for
these types of investigations4-10; however, we are not going to focus on those methods. We will
first review the history of studying pleiotropy in human genome. Next, we outline the analytical
approaches for either common genetic variants or rare genetic variants. Finally, we discuss
challenges and future directions for uncovering pleiotropy from large-scale biomedical datasets.

1.3

History of studying pleiotropy in human genome
The term pleiotropy was first defined by the geneticist Ludwig Plate in 1910. In the late

1970s, researchers started to learn the mechanisms of pleiotropy at a molecular level in model
organisms11. For instance, fundamental questions have been addressed in model organisms,
such as the number of traits that can be influenced by pleiotropy and the multiple functions of
certain genes12-17. Research on pleiotropy in humans is only at the beginning of its era. With the
advancement of sequencing technologies, curation of large-scale datasets, and effective
statistical methods, a broad genotype to phenotype map is being established; this is enabling
pleiotropy to be more thoroughly investigated in humans.
2

Genome-wide association studies (GWAS) have identified more than 200,000 variants
associated with a wide range of traits18,19. An interesting observation is that many GWAS loci
have been found to be associated with multiple traits, also known as cross-phenotype
associations20. Cross-phenotype associations may harbor pleiotropy, though it is important to
note that pleiotropy is only one of the possible underlying causes for cross-phenotype
associations 20. An overview of the GWAS catalog suggested that 90% of GWAS loci are
associated with more than one trait21, which implies that there may be ubiquity of pleiotropy
across the human genome.
Most studies of pleiotropy are inferred using independent single phenotype GWAS
approach. Each GWAS was focused on one specific trait, therefore, the inference of pleiotropy
must be drawn using only the GWAS summary statistics across many independent studies.
Interestingly, both concordant and discordant pleiotropy have been identified among immunemediated diseases22; similar observations have been seen across eight psychiatric disorders as
well23. Combining multiple GWAS studies offers invaluable insights into biology. However, since
each study has its own unique disease definition, study design, and statistics models, there may
be bias in the estimates for pleiotropy due to these inconsistencies, which reduce power for
methods that were designed for summary statistics only. Moreover, most published GWAS focus
on relatively common diseases, which makes finer, more rare clinical phenotypes largely
unstudied.
EHR-linked biobank datasets have great potential for exploring and discovering pleiotropy.
EHRs provides a comprehensive phenotype landscape for each patient-participant from the
biobank, which allows for the expansion of focus from a single disease to a whole spectrum of
diseases phenotypes. Using a broad set of phenotypes can be powerful for identifying pleiotropy
by providing the entire phenome for each participant; and it also enables researchers to conduct
robust study designs, such as the use of a discovery-replication scheme. With the application of
3

effective statistical methods on individual-level genetics and phenotype data, EHR-linked
biobanks could offer the opportunity for robust inferences about pleiotropy. Fortunately, impactful
EHR-linked biobanks are being developed, such as the UK Biobank24, the Million Veteran
Program25, All of Us, the Penn Medicine Biobank, and the set of EHR-linked biobanks affiliated
with the eMERGE network26. We believe that EHR-linked biobanks will provide the resources
needed to shed light on the shared biology underlying various traits, thus assisting in our
understanding of fundamental biology as well as drug discovery and repositioning in near future.

1.4

Pleiotropy methods for common variants
Analytical methods for identifying pleiotropy for the association of common genetic variants

with phenotypes can be broadly categorized into univariate, multivariate, and sequential
multivariate association methods. We review current methodologies and discuss the advantages
and disadvantages for each category of methodology.

1.4.1

Univariate association methods

The univariate association method refers to the statistical model that tests the association
between one phenotype and one genetic variant at a time27. GWAS is an example of the most
widely used univariate approach. In a GWAS, any association statistic can be used, depending
on the phenotype, such as logistic regression or linear regression. A chi-square test of
association can also be used. In the context of pleiotropy, a univariate approach scans the
genome, testing for the association of each common genetic variant, with each phenotype across
the phenome. This results in a genome-wide, phenome-wide association analysis which provided
the opportunity to make inferences about potential pleiotropy. Since summary statistics are
derived from single phenotype association tests, the term univariate method also has been used
to describe methods that combine GWAS summary statistics. There are several reviews have
discussed those methods extensively28-30. Since we are interested in methods that can be applied

4

specifically to EHR-linked biobanks, we are focusing only on discussing methods that are
designed for individual-level data.
The test for univariate associations across a wide range of phenotypes is called a phenomewide association studies (PheWAS). PheWAS builds a genotype-to-phenotype map for every
genetic variant across hundreds of phenotypes31-34. The inference of pleiotropy for common
variants can be observed by evaluating the cross-phenotype associations from PheWAS.
PheWAS has demonstrated the potential to identify pleiotropy in multiple studies such as
Electronic Medical Records and Genomics (eMERGE) network35 and the Population Architecture
using Genomics and Epidemiology (PAGE) study36. The choice of statistical method largely
depends on the type of phenotype being tested. For disease status (binary outcome), logistic
regression can be applied. For quantitative traits (continuous outcome), linear regression can be
applied. Statistical models can also be adjusted for the desired covariates obtained from the
health records of the biobank participants. These may include age, race/ethnicity, sex, or body
mass index to name a few. A number of different software packages can be used to perform
these types of univariate analyses include PLINK37, PLATO38, SAIGE39, Regenie40.
One advantage of the univariate association method is its ability to provide a detailed map
for each genotype-phenotype pair. The genetic effect size obtained from the univariate
association tests indicates the direction of the genetic effect as well as the magnitude of the effect
that the genetic variant has on phenotype. On the flip side, the number of tests being performed
increases with the number of phenotypes being tested, thus, multiple testing corrections should
be considered for univariate association tests. However, using a stringent p-value threshold, like
a Bonferroni correction for all genetic variants and all phenotypes, may lead to a high false
negative rate, where true associations do not reach the multiple testing p-value threshold. As
such, there is a balance between false positive rates and false negative rates that needs to be
considered for interpreting pleiotropy from univariate association results.
5

1.4.2

Multivariate association methods

Multivariate association methods describe statistical methodology that jointly tests two or
more phenotypes simultaneously27. This type of methodology often requires individual-level data,
and the phenotypes need to be measured and available for each patient-participant. From
electronic health records, disease status or biometric measurements are available for most of the
participants, making these data suitable for identifying genetic variants that are associated with
multiple traits using multivariate association methods. One benefit of multivariate association
method is that they tend to have higher power than univariate association methods as these
methods can account for the covariance among traits30; this makes multivariate association
methods favorable for the discovery of pleiotropy in EHR-linked biobank datasets.
The choice of multivariate association method will largely depend on the type of phenotype
under consideration. There are numerous different multivariate association methods proposed for
analyzing continuous traits. For example, multivariate linear mixed models (mvLMMs) are
powerful methods for testing associations among correlated traits, while accounting for population
stratification and sample relatedness41. The phenotypic input data for mvLMMs should be
multivariate normally distributed41. A similar method that requires a multivariate normal input is
BIMBAM, which is developed based on a Bayesian model and is suitable for a modest number of
phenotypes (e.g. 5-10)42. Dimensionality reduction methods, such as principal component
analysis methods, have also been proposed for multivariate association approaches43,44. As for
binary traits, several methods have also been developed, including MultiPhen45 and reduced-rank
regression46. MultiPhen implements an ordinal regression with the genotype being the response
variable and the phenotypes being predictor variables. MultiPhen captures the linear combination
of the most associated phenotypes for each genetic variant45. The reduced-rank regression is a
dimensionality reduction method that can identify important patterns by restricting the rank in the
coefficient matrix; this approach allows for testing multiple genotypes with multiple phenotypes
simultaneously46.
6

The advantage of multivariate association methods over univariate association methods is
their ability to account for the relationship or correlation among multiple phenotypes. Multivariate
association methods have demonstrated their increased power in several simulation settings29,30.
These methods also have a reduced multiple testing correction burden due to the joint test of
multiple traits28, rather than multiple separate tests. However, given that the rejection of the null
hypothesis suggests association with ‘one or more traits’, most of the multivariate frameworks do
not necessarily fulfill the requirement for pleiotropy – which needs at least two traits. So, it could
be that the multivariate association test has a p-value that is statistically significant whereby the
null hypothesis is rejected; however, there is only one trait that is associated, rather than two.
Thus, this would not be pleiotropy. Also, the significance of the multivariate p-value does not
indicate which exact trait(s) are associated with the SNP, thus it is challenging to interpret
pleiotropy solely from multivariate association results. Often, an additional downstream analysis is
needed to decompose which traits are associated. For example, performing a univariate
association test where you see significant multivariate association may assist with the
interpretation of the multivariate results. Indeed, it has been suggested to view both univariate
association and multivariate association methods as complementary rather than competing
methodologies41.

1.4.3

Sequential multivariate association methods

Sequential multivariate association methods, also known as ‘formal test of pleiotropy’, have
been developed to address the above-mentioned challenge facing multivariate method ¾ inability
to pinpoint the exact set of associated traits. Schaid et al. proposed a sequential multivariate
method called ‘pleio’, which performs multivariate generalized linear models iteratively47. The
input phenotype can be binary, ordinal, or continuous. This approach tests the null hypothesis
that k+1 traits are associated with the genetic variant, given that the null of k associated traits was
rejected. By performing multivariate analysis sequentially, this powerful method can pinpoint the
7

exact set of phenotypes that are associated with the genetic variant, thus, a researcher can
discover pleiotropy based on their associated phenotypes of interests.
This type of method offers a robust estimation of the phenotypes that are associated with
each SNP. However, as the number of associated phenotypes increases, the iterations needed to
find which combinations of phenotypes are associated increases drastically. Because of this,
pleio works well for small to moderate numbers of phenotypes (such as less than 65), but would
be extremely time-consuming if too many associated phenotypes are present in the dataset.
Another drawback of pleio is that, in a similar vein as the general multivariate association method
framework, the genetic effect size is unknown for each genotype-phenotype pair. Univariate
results could be helpful to resolve this challenge. Again, like with multivariate methods, univariate
association results can be helpful to resolve this challenge with sequential multivariate methods
like pleio.

1.5

Pleiotropy methods for rare variants
In addition to common genetic variants, rare genetic variants are also important to improve

our understanding of pleiotropy. Methods for single locus association analysis are underpowered
for rare variants due to their low frequency, unless the effect size is very large48. Generally,
grouping rare variants into regions (e.g. genes or pathways) assists in the discovery of rare
variant associations as these groupings of rare variants can increase statistical power48. In the
next sections, we review the region-based tests for rare variants and describe in their potential for
identifying pleiotropy.

1.5.1

Univariate Association Methods

Here, univariate association methods refer to the association between one biological region
and one phenotype per statistical model. Methods in this category can be grouped into burden
and dispersion tests, which are two categories of standard methods in rare variant association
8

studies. In the context of pleiotropy, univariate methods can be applied across the phenome to
characterize pleiotropic genes/regions that are associated with traits of interests. For instance,
Park et al. characterized novel predicted loss-of-function genes via an exome-by-phenome
scheme using burden tests in the Penn Medicine Biobank49. Software such as rvtest50 and
BioBin51 offer multiple choices of statistical models and weighting schemes for these types of
univariate association tests. Users can refer to the software manuals and perform the analysis
according to the type of phenotype (binary, continuous, or ordinal), adjustment for covariates,
research hypothesis being tested, etc. A recent proposed method ‘SKAT-robust’ can account for
unbalanced case-control sample size using saddle point approximation and efficient resampling52.
Within these methods, much like for the common variant univariate association methods, multiple
testing can be an issue of concern as these methods do one statistical test per gene/region and
per phenotype. Thus, with a large number of phenotypes and a genome-wide burden or
dispersion test, there can be a hefty multiple testing burden.

1.5.2

Multivariate association methods

Multivariate association methods refer to performing rare variant association tests across a
set of multiple phenotypes jointly. This type of method is in its early development. Here, we
review a few proposed methods. For continuous traits, MultiSKAT implements a multivariate
kernel regression to jointly analyze multiple phenotypes53. In addition to continuous traits,
KMgene can also handle continuous longitudinal, survival and binary family data54. Another tool
called MARV55 can take both binary and continuous phenotypes, however, it seems that it does
not allow for adjustment of covariates. Methods that can handle binary traits include adaptive
weighting reverse regression (AWRR)56, weighted sum reverse regression (WSRR)56 and
multivariate association analysis using score statistics (MAAUSS)57. AWRR performs a reverse
regression with phenotypes as predictor variables and collapsing genotype as the outcome or
response variable56. WSRR is developed using the same ideas as AWRR but uses the Madsen
9

and Browning weighting scheme and has been suggested to be less powerful than AWRR.
MAAUSS extends the SKAT framework to multiple phenotypes57. However, to our knowledge, the
software for these multivariate rare variant association methods are not readily available to the
scientific community yet.

1.6

Challenges and future directions
Unfortunately, there is no single statistical method that is the most powerful and can cover all

of needed information for a robust and thorough investigation of pleiotropy across the human
genome. It is currently recommended to use an ensemble of methods to maximize the ability to
identify pleiotropy. For example, we recently conducted a study where we applied multiple
association methods and characterized pleiotropy for common variants across cardiovascular and
neurological diseases from the eMERGE network58. In this study, we observed that different
signals can be detected by using different methods, which suggest that the association results
are largely driven by the chosen statistical method(s). With the application of multiple powerful
methods, one can hope to provide a relatively complete picture of the genotype-to-phenotype
relationships and to understand pleiotropy.
For common variant association methods, one possible future direction is to develop efficient
and powerful tools to characterize pleiotropy. As discussed above, the multivariate association
framework is, in general, more powerful than a univariate framework. However, in order to
address the challenges facing multivariate methods, sequential multivariate approaches have
been developed. These methods are more powerful but less computationally efficient, especially
given a large number of associated phenotypes. Pre-selection of a set of phenotypes using
thresholding or dimensionality reduction techniques could be helpful. On the other hand,
currently, the interpretation of pleiotropy from multivariate models needs to take univariate results
into consideration. Perhaps future sequential multivariate methods will provide the specificity of
which traits show evidence of pleiotropy and remove the need for the complementary univariate
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association analysis. With the application on large-scale EHR-linked biobanks, a unified and
efficient analytical approach that addresses these challenges would be beneficial.
Multivariate association methods for rare variants is still in their infancy. We would expect to
see more multivariate rare variant methods becoming available for use on EHR-linked biobank
data in the future, especially given the increasingly expanding whole exome sequencing data
available in the scientific community. Possible functional annotation and filtering strategies could
assist in the understanding of the influence of pleiotropy on the human genome. A promising
future is to combine the pleiotropy association results from common variants along with
information about the nearby regulatory regions as well as functional rare variants. In this way,
researchers can link often non-coding common variants to the functional rare variants across
multiple traits to elucidate the architecture of pleiotropy as a whole.

1.7

Conclusions
Understanding pleiotropy is crucial to elucidate the genetic architecture of complex traits.

With the accumulation of rich genetics datasets linked with deep phenotypes, charactering
pleiotropy in the human genome became has become more possible and very exciting. In this
review, we covered the current state of analytical methods for identifying pleiotropy in EHR-linked
biobank datasets. We offered an overview of the current stages for statistical methods for
identifying pleiotropy in common genetic variants and rare genetic variants. We discussed the
assumptions for choosing the desired methods, serving as a reference for the researchers.
Meanwhile, we outlined advantages and disadvantages for each method category, followed by a
discussion on the challenges and future directions in the field. Large-scale EHR-linked biobank
datasets are expanding at a fast pace, with the application of effective statistical methods,
pleiotropy can be captured and will help with the understanding of human biology. Improving our
understanding of pleiotropy could assist future disease risk prediction, minimizing drug side
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effects, possible drug repositioning, and preventive identification and care for vulnerable
populations.

1.8

Outline for dissertation
In Chapter 1, we review current analytical approaches for detecting pleiotropy in EHR-linked

biobank datasets, for common variants and rare variants respectively. The review is focused on
the univariate and multivariate association methods designed for individual level data. We also
discuss the challenges and future directions in this topic.
Since most of previously published simulation studies were conducted using a balanced
case-control sample size, the statistical performance for unbalanced case control scenarios are
largely unknown. For common variants, the impact of sample size imbalance for univariate
association methods has been discussed previously59. In Chapter 2, we design a large-scale
simulation study for unbalanced case-control scenarios for multiple related traits. The statistical
performance for univariate and multivariate methods on common variants is also carefully
evaluated. As for the application, a case study of five traits with sample size imbalance in the UK
Biobank has been included in this chapter.
In Chapter 3, we present our pilot study on identifying pleiotropy across circulatory system
diseases and nervous system disorders in the eMERGE network. In Chapter 4, we conduct our
analyses using a discovery-replication scheme on two independent biobank datasets, the
eMERGE network and the UK Biobank. We implement a unified analytical framework and present
pleiotropic regions that are associated with circulatory system diseases and nervous system
disorders. We demonstrate disease relationships that can be linked by the discovery of
pleiotropy.
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In Chapter 5, we investigate the sample size imbalance for univariate rare variant
association study. We characterize statistical performance for two widely used association
methods – burden and dispersion tests across a wide range of sample size designs. In Chapter 6,
we apply both burden and dispersion tests on the whole-exome sequencing data from the UK
Biobank and characterize pleiotropic genes that are associated with circulatory system diseases
and nervous system disorders.
In Chapter 7, we conclude the dissertation and discuss future directions in the field of
identifying pleiotropy in the EHR-linked biobank datasets. We also discuss possible future
applications of pleiotropy for clinical practice and the pharmaceutical field.
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CHAPTER 2 Statistical impact of sample size and imbalance on multivariate
analysis in silico and a case study in the UK Biobank

This chapter was adapted from:
Xinyuan Zhang, Ruowang Li, Marylyn D. Ritchie. (2020) “Statistical Impact of Sample Size and
Imbalance on Multivariate Analysis in silico and A Case Study in the UK Biobank”. Accepted.
XZ and MDR conceptualized the project. XZ led the project. XZ contributed to designing the
analysis, performing the analysis and manuscript writing. RL assisted with analysis design and
RL and MDR provided important feedback on the manuscript. All the authors read and approved
the final manuscript.

2.1

Abstract
Large-scale biobank cohorts coupled with electronic health records offer unprecedented

opportunities to study genotype-phenotype relationships. Genome-wide association studies
uncovered disease-associated loci through univariate methods, with the focus on one trait at a
time. With genetic variants being identified for thousands of traits, researchers found that 90% of
human genetic loci are associated with more than one trait, highlighting the ubiquity of pleiotropy.
Recently, multivariate methods have been proposed to effectively identify pleiotropy. However,
the statistical performance in natural biomedical data, which often have unbalanced case-control
sample sizes, is largely known. In this work, we designed 21 scenarios of real-data informed
simulations to thoroughly evaluate the statistical characteristics of univariate and multivariate
methods. Our results can serve as a reference guide for the application of multivariate methods.
We also investigated potential pleiotropy across type II diabetes, Alzheimer’s disease,
atherosclerosis of arteries, depression, and atherosclerotic heart disease in the UK Biobank.
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2.2

Introduction
Understanding genetic factors that contribute to disease susceptibility is the center of human

genetics research. Genome-wide association studies (GWAS) have uncovered thousands of
genetic variants that are associated with complex diseases. A recent study found that 90% of
these GWAS significant loci are associated with multiple diseases, suggesting widespread
pleiotropy in the human genome21. Pleiotropy describes a variant or a gene that influences more
than one phenotype and plays a critical role in many aspects of biology1,11,20. Univariate and
multivariate methods are two types of statistical methods that can be applied to detect genetic
associations with multiple diseases28. Univariate models focus on one phenotype at a time, such
as GWAS, while multivariate methods jointly model the association across multiple phenotypes
simultaneously. Previous studies demonstrated that multivariate methods have higher power than
univariate methods, which holds great potential in discovering pleiotropy with multivariate
methods. However, previous simulations were based on quantitative traits or balanced sample
sizes (equal numbers of cases and controls)29,30,60. With the application to natural biomedical
data, it is beneficial to acquire the expected type I error and power under unbalanced sample size
scenarios.
Sample size imbalance is a key feature of natural biomedical data. The wide range of
disease prevalence in the population introduces different case control sample size to the human
phenome. For instance, phenome-wide association studies evaluate the genetic association
across hundreds and thousands of diseases obtained from electronic health records3,31, with
varying case control sample sizes. Most of the statistical methods are developed based on the
balanced case control assumptions. With the application of statistical methods to natural
biomedical data, it is crucial to understand the statistical characteristics under real-world
scenarios. The role of sample size imbalance has been previously studied for univariate methods
for both common and rare variants59,61. However, to our knowledge, the impact of sample size
imbalance on multivariate analyses is largely unknown.
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Here, we conducted a natural biomedical data informed simulation study to evaluate
univariate and multivariate methods in identifying pleiotropy for binary phenotypes with different
sample sizes. We designed 21 scenarios of various degrees of sample size imbalance and
characterized type I error and power for logistic regression and MultiPhen45. MultiPhen is chosen
in our study because it is designed for studying binary traits and has sufficient statistical power30.
The correlation structure used in the simulation was obtained from selected traits with different
case sample sizes from the UK Biobank. Our simulation results provide the landscape of type I
error and power of univariate and multivariate methods under various scenarios, thus providing a
potential reference guide for the application of these methods to natural biomedical data.
Furthermore, it has been previously suggested that studying pleiotropy in large biobank cohorts
coupled with electronic health records provides novel insights into biology31,34,36,58,62. As a case
study, we applied logistic regression (univariate method) and MultiPhen (multivariate method) to
investigate potential pleiotropy across type II diabetes, Alzheimer’s disease, atherosclerosis of
arteries, depression, and atherosclerotic heart disease in the UK Biobank.

2.3

Methods
2.3.1

Simulation Design

We designed 5 balanced and 16 unbalanced case sample size scenarios (Table 2.1) with a
total sample size of 10,000. For balanced case sample size design, each trait has the same case
sample size across five traits, e.g. 100 cases for all five traits (Table 2.1). Our simulation was
performed via a multivariate binary phenotype generation tool ‘bindata’ R package180. An example
of our simulation code is provided at the end of this manuscript, and we also deposited our
simulation code on GitHub [https://github.com/blairzhang126/Multivariate-Sim]. We simulated 10
replicates for each scenario, with 100 independent datasets per replicate. We simulated one
common genetic variant per dataset, with a minor allele frequency of 0.05. The simulation of the
genetic variant is based on Hardy-Weinberg equilibrium. The genetic effect size was set as 0 for
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type I error simulations and 0.3 for power evaluations. The disease prevalence was set to achieve
the desired case sample size. Phenotype correlation was estimated from five selected
phenotypes given their case sample sizes (Table 2.2) from European individuals in the UK
Biobank3 based on the following ICD-10 codes: severe depression episode without psychotic
symptoms (F32.2), adjustment disorders (F43.2), other forms of angina pectoris (I20.8), other
forms of chronic ischaemic heart disease (I25.8) and unspecified cardiomyopathy (I42.9).

Table 2.1 Case Sample Size Design
Balanced Case Sample Size for Each of Five Traits
100
200
300
400

500

Labels in plot
Scenario1-5

Unbalanced Case Sample Size across Five Traits
Trait1
Trait2
Trait3
Trait4
100
100
100
100
100
100
100
500
100
100
500
500
100
500
500
500
200
200
200
200
200
200
200
500
200
200
500
500
200
500
500
500
300
300
300
300
300
300
300
500
300
300
500
500
300
500
500
500
400
400
400
400
400
400
400
500
400
400
500
500
400
500
500
500

Trait5
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500

Scenario6
Scenario7
Scenario8
Scenario9
Scenario10
Scenario11
Scenario12
Scenario13
Scenario14
Scenario15
Scenario16
Scenario17
Scenario18
Scenario19
Scenario20
Scenario21

2.3.2

Type I error and Power calculation

For each replicate, we simulated 100 independent datasets. For MultiPhen, Type I error and
power were calculated as the number of datasets with a p-value less than 0.05 out of 100 total
datasets. The p-value threshold for logistic regression was 0.01, as corrected for multiple testing
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burden across five traits (calculated as 0.05/5). Each bar in the bar plot in the results section
represents the type I error or power obtained from 10 replicates. The plots of simulation results
were generated using ggplot2 R package64.

2.3.3

Quality Control in the UK Biobank

Our analyses were performed on white British individuals from the UK Biobank. We followed
quality control procedure described in the previous literature24. We excluded poor quality samples
that had a sample missing rate higher than 5% and an unusual heterozygosity24, and individuals
who were closer than 2nd degree relatives. We further removed the samples with sex
mismatches. Among the rest of them, we included individuals whose phenotype and covariate
information are available. For imputed genotype data, we performed our analysis on the common
variants with a minor allele frequency of ≥ 0.01 and had an imputation info score of ≥ 0.3. We
applied a linkage disequilibrium filtering to select independent SNPs with “--indep-wise 1000 80
0.1” in PLINK37. In total, there are 214,318 SNPs and 295,423 white British individuals included in
our subsequent analyses.

2.3.4

Association Analyses in the UK Biobank

We defined our phenotypes based on the ICD-10 codes, and selected five traits that consist
of unbalanced case sample sizes (Table 2.2). We performed logistic regression and MultiPhen on
individuals and genetic variants that passed quality control. All of the association models were
adjusted by age, genetic inferred sex, genotyping array and first 20 principal components. There
were in total 1,071,590 tests being performed for logistic regression and the Bonferroni correction
threshold is 4.67*10-8 (calculated as 0.05/(214318*5)). For MultiPhen, the Bonferroni threshold is
2.33*10-7 (calculated as 0.05/214318).

18

Table 2.2 Phenotypes and Case Sample Size from UK Biobank

ICD10 Description

Broad disease category

Case sample
size
(after quality
control)

E11.9

Type II diabetes without
complications

Endocrine, nutritional and
metabolic diseases

16,516

F32.3

Severe depressive episode
with psychotic symptoms

Mental, behavioral and
neurodevelopmental
disorders

236

G30.9

Alzheimer’s disease

Diseases of the nervous
system

325

I70.2

Atherosclerosis of arteries
of the extremities

Diseases of the circulatory
system

501

I25.1

Atherosclerotic heart
disease

Diseases of the circulatory
system

16,932

2.4

Results
We observed an overall controlled type I error for all of the simulation scenarios (Figure 2.1).

We observed comparable type I error rates for logistic regression and MultiPhen and most of the
values are less than 0.1. The mean of type I error across 10 replicates is around 0.05 for all
simulation scenarios (Figure 2.1). Even with varying degrees of case sample size imbalance
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across the five traits, we did not observe an obvious trend between sample size imbalance and
type I error under our simulation settings.

Figure 2.1 Type I error Simulation Results. Each bar in the bar plot represents the
distribution of Type I error from 10 replicates. Scenarios 1-5 are simulated based on balanced
sample size, while others are simulated based on the unbalanced sample size.

For balanced case sample size settings (scenarios 1-5), we observed an increasing trend of
power with the increase of case sample size (Figure 2.2). And case numbers of more than 200
(scenario 3-5) yield a mean of statistical power of >60%. For unbalanced case sample size
scenarios (6-21), we observed the increase of power when adding more traits with larger case
sample sizes (refer to Table 2.1). We have also observed the baseline power for each set
(scenario 6,10,14,18) increases as the case sample size increases. Interestingly, we see that
MultiPhen has higher power than logistic regression for most of the simulation scenarios (Figure
2.2).
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Figure 2.2 Power Simulation Results. Each bar in the bar plot represents the distribution of
power from 10 replicates. Scenarios 1-5 are simulated based on balanced sample size, while others
are simulated based on the unbalanced sample size.

We demonstrated our univariate and multivariate results from the UK Biobank in a Hudson
plot (Figure 2.3) (https://github.com/anastasia-lucas/hudson). The SNPs evaluated in our study
are independent from each other with the R-squared less than 0.1 (see Methods). We observed
very similar patterns of the associations identified by logistic regression and MultiPhen (Figure
2.3). In total, we observed 22 Bonferroni significant variants identified by MultiPhen, and 32
Bonferroni significant variants by logistic regression. Interestingly, Bonferroni significant variants
identified by MultiPhen have all been identified by logistic regression (Figure 2.4).
We observed a missense common variant rs11591147 located on PCSK9 gene on
chromosome 1, which is associated with atherosclerotic heart disease (p-value: 6.029 * 10-11).
PCSK9 protein regulates cholesterol in the bloodstream and has been suggested to play a role in
atherosclerosis67. SNP rs10738609 on chromosome 9 is an intron variant that is located at
CDKN2B-AS1 gene, which is a known hot spot gene for cardiovascular diseases68. We observed
its significant association (univariate p-value: 3.252 * 10-76) with atherosclerotic heart disease in
our study. We further looked at its association with other tested diseases and observed its
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association with type II diabetes (univariate p-value: 1.461 * 10-5) and a moderate level of
association with atherosclerosis of arteries (univariate p-value: 0.0003428).

Figure 2.3 Hudson Plot of Univariate and Multivariate Results. The top plot is the result
of univariate analysis and the bottom plot is the result of multivariate analysis. The red line
denotes the Bonferroni threshold. X-axis stands for the genomic position across 22
chromosomes; Y-axis stands for the -log10(p-value). Color in the top plot denotes the phenotype.
In the top plot, color denotes diseases: red denotes ICD-10 code of E11.9; green denotes ICD-10
code of F32.3; purple denotes ICD-10 code of G30.9; yellow denotes ICD-10 code of I25.1; dark
red denotes ICD-10 code of I70.2. In the bottom plot, because the phenotypes are jointly
analyzed, we use blue to denote the results from MultiPhen analysis.

22

Figure 2.4 Venn Diagram of the Bonferroni Significant Variants Identified by Logistic
Regression and MultiPhen
There are 15 Bonferroni significant variants that are associated with type II diabetes. We
identified one genetic variant SNP rs8047395 located on chromosome 16 near FTO gene
(univariate p-value: 5.607 * 10-12), which is a previously known genetic variant that is associated
with type II diabetes69. We also identified a known SNP rs76895963 to be associated with type II
diabetes18,19. SNP rs2673142 showed a moderate significant association with depression (pvalue: 0.00034) in addition to type II diabetes.
For depression, we identified one novel variant rs548613298 that is associated with
depression from our analysis. For Alzheimer’s disease, both methods identified three Bonferroni
significant genetic variants located on chromosome 19 near APOC1/APOE region (rs12691088,
rs79701229 and rs60049679). The region was known to have a strong association with
Alzheimer’s disease70,71. These three genetic variants showed a moderate significant association
with atherosclerotic heart disease (with univariate p-values around 0.005). As for atherosclerosis
of arteries, we did not observe any Bonferroni significant variant.
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2.5

Discussion
Type I error was mostly controlled under 0.1 for our simulation scenarios. We did not

observe an obvious impact of sample size imbalance on type I error (Figure 2.1). We found that
statistical power increases as the number of phenotypes with larger case sample size increases
(Figure 2.2). We also observed an elevation of statistical power for unbalanced case sample
sizes when adding more phenotypes with 500 cases. MultiPhen outperforms logistic regression
on many sample size imbalance simulation settings (Figure 2.2). Multivariate methods previously
demonstrated higher power than logistic regression45 under balanced sample size, and our work
demonstrated the same trend in sample size imbalance scenarios.
For our case study in UK Biobank, we performed logistic regression and MultiPhen analyses
across type II diabetes, atherosclerotic heart disease, depression, Alzheimer’s disease and
atherosclerosis of arteries. We identified many previously known genetic variants as well as novel
variants. We demonstrated the effectiveness of applying both methods in identifying pleiotropy.
There were 22 Bonferroni significant variants being identified by MultiPhen, which have all been
identified by logistic regression. The reason that MultiPhen has identified lesser number of
significant variants might due to its limited power in scenarios when the genetic effect is
inconsistent with the phenotypic correlation45. By applying both methods, it assists us to limit the
false positives in the discovery of pleiotropy as well as help with the interpretation of the results.
One limitation of the present study is that only genetic risk was considered. Future work on
protective genetic effect and a mixture of both directions of genetic effect is needed to
comprehensively understand the power of these methods. Evaluating additional scenarios that
may provide more understanding of the inflation of type I error, which likely also lead to higher
power for MultiPhen, would be also warranted. While controlled at a rate of 0.10 or less, it would
be beneficial to get the type I error controlled under 0.05 or less if possible. As for the case study,
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we only investigated the independent SNPs. Future study on more coverage of the genetic
variants would shed more light on the biology.
In this work, we conducted a natural biomedical data-informed simulation study to
characterize statistical performance of univariate and multivariate methods in detecting genetic
associations with multiple phenotypes. Our design of sample size imbalance offers a new
perspective of the statistical performance of these methods, which would greatly assist future
discovery of pleiotropy. Our case study showcases the effectiveness of applying univariate and
multivariate methods in identifying pleiotropy in large-scale biobank cohort.

2.6

Simulation code example

#R code for simulating 100 balanced case sample size for power
evaluation. This code is for simulating 5 traits.
library(bindata)
library(MultiPhen)
n=10000
maf=0.05
#User can specify different beta0 to control case sample size
beta0=c(-4.6,-4.6,-4.6,-4.6,-4.6)
x<-sample(c(0,1,2),n,replace=T,prob=c((1-maf)*(1-maf),2*maf*(1maf),maf*maf))
x<-as.matrix(x)
#User can specify different beta to control the effect sizes of the
SNPs
beta=c(0.3,0.3,0.3,0.3,0.3)
#User can input a phenotype matrix which they wish to produce the
correlation matrix for simulated traits. Here I'm posting an example of
the correlation matrix (b_cor) among 5 traits that described in the
manuscript.
b_cor<-matrix(c(1.0000000000,0.0415276512,0.0007543885,0.001951613,0.001077797, 0.0415276512, 1.0000000000, 0.0008421039, 0.005441721,
0.002168689, 0.0007543885, 0.0008421039, 1.0000000000, 0.098728472,
0.003179557, 0.0019516132, 0.0054417214, 0.0987284719, 1.000000000,
0.029784037, -0.0010777969, 0.0021686888, 0.0031795574, 0.029784037,
1.000000000),nrow=5,ncol=5,byrow=TRUE)
prob<-matrix(nrow=10000, ncol=5)
prob[,1]<-exp(beta0[1]+x %*% t(beta[1]))/(1+exp(beta0[1]+x %*%
t(beta[1])))
prob[,2]<-exp(beta0[2]+x %*% t(beta[2]))/(1+exp(beta0[2]+x %*%
t(beta[2])))
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prob[,3]<-exp(beta0[3]+x %*% t(beta[3]))/(1+exp(beta0[3]+x %*%
t(beta[3])))
prob[,4]<-exp(beta0[4]+x %*% t(beta[4]))/(1+exp(beta0[4]+x %*%
t(beta[4])))
prob[,5]<-exp(beta0[5]+x %*% t(beta[5]))/(1+exp(beta0[5]+x %*%
t(beta[5])))
y<-t(apply(prob, 1, function(m) rmvbin(1, margprob=m, bincorr=b_cor)))
colnames(y) <-c("Trait_1","Trait_2", "Trait_3", "Trait_4", "Trait_5")
logistic.out1 <- glm(y[,1] ~ x[,1],family=binomial)
tmp1 <- summary(logistic.out1)[[12]][2,]
logistic.out2 <- glm(y[,2] ~ x[,1],family=binomial)
tmp2 <- summary(logistic.out2)[[12]][2,]
logistic.out3 <- glm(y[,3] ~ x[,1],family=binomial)
tmp3 <- summary(logistic.out3)[[12]][2,]
logistic.out4 <- glm(y[,4] ~ x[,1],family=binomial)
tmp4 <- summary(logistic.out4)[[12]][2,]
logistic.out5 <- glm(y[,5] ~ x[,1],family=binomial)
tmp5 <- summary(logistic.out5)[[12]][2,]
tmp<-cbind(tmp1,tmp2,tmp3,tmp4,tmp5)
tmp_t<-t(tmp)
write.table(tmp_t,file="run1.logistic.output",quote=F,row.names=T,col.n
ames=T,sep='\t')
y<-as.matrix(y)
rownames(y)<-seq(1:10000)
rownames(x)<-seq(1:10000)
mPhen_out <- mPhen(x[,1, drop=FALSE], y, phenotypes = all, resids =
NULL, covariates=NULL, strats = NULL,opts =
mPhen.options(c("regression","pheno.input")))
mPhen_jointp <- mPhen_out$Results[,,,2][6]
write.table(mPhen_jointp, file="run1.multiphen.output", col.names=T,
row.names=T, sep="\t",quote=F)
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3.1

Abstract
The link between cardiovascular diseases and neurological disorders has been widely

observed in the aging population. Disease prevention and treatment rely on understanding the
potential genetic nexus of multiple diseases in these categories. In this study, we were interested
in detecting pleiotropy, or the phenomenon in which a genetic variant influences more than one
phenotype. Marker-phenotype association approaches can be grouped into univariate, bivariate,
and multivariate categories based on the number of phenotypes considered at one time. Here we
applied one statistical method per category followed by an eQTL colocalization analysis to identify
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potential pleiotropic variants that contribute to the link between cardiovascular and neurological
diseases. We performed our analyses on ~530,000 common SNPs coupled with 65 electronic
health record (EHR)-based phenotypes in 43,870 unrelated European adults from the Electronic
Medical Records and Genomics (eMERGE) network. There were 31 variants identified by all
three methods that showed significant associations across late onset cardiac- and neurologicdiseases. We further investigated functional implications of gene expression on the detected
“lead SNPs” via colocalization analysis, providing a deeper understanding of the discovered
associations. In summary, we present the framework and landscape for detecting potential
pleiotropy using univariate, bivariate, multivariate, and colocalization methods. Further exploration
of these potentially pleiotropic genetic variants will work toward understanding disease causing
mechanisms across cardiovascular and neurological diseases and may assist in considering
disease prevention as well as drug repositioning in future research.

3.2

Introduction
Cognitive decline has been observed in nearly 42% of elderly individuals at five years after

cardiac surgery72. Of late, there has been increasing clinical evidence suggesting a link between
cardiovascular and neurological diseases. To facilitate efficient disease prevention and treatment
for cardiovascular and neurological diseases, it is imperative to understand the underlying, often
unexplained, disease-causing mechanisms across multiple phenotypes. Pleiotropy is a
phenomenon that can explain the influence of a specific allele on two or more unrelated
phenotypes. While there has been evidence of polygenic pleiotropy (where multiple variants are
causally associated with multiple traits) among cardiovascular73 and neurological diseases74,
recent work has also demonstrated a genetic basis for the link between these disease groupings.
In particular, there has been evidence of genetic overlap between cardiovascular disease and (a)
multiple sclerosis75 as well as (b) schizophrenia76. Large-scale genomics data coupled with
electronic health record (EHR) data can enhance our ability to uncover novel cross phenotype
associations and potentially pleiotropic variants (cross-phenotype association could also be an
28

artifact of linkage disequilibrium (LD) or disease co-morbidities rather than true pleiotropy)3. In
this study, we sought to identify common genetic variants that contribute to the link between
diseases of the circulatory and nervous system using 43,870 unrelated European adults and 65
disease phenotypes from the Electronic Medical Records and Genomics (eMERGE) network.
Statistical approaches to detect pleiotropy across multiple phenotypes can be univariate
(CPMA6, ASSET77, MultiMeta9, GPA10, MTAG4, etc.), bivariate, and multivariate (MTMM78,
MultiPhen45, GEMMA41, mvLMM79, mvBIMBAM42, etc.) in addition to network-based approaches,
among others80. Univariate methods (e.g. Phenome wide association studies or PheWAS) are a
powerful way to characterize the effect of a genetic variant on each phenotype independently,
and potential pleiotropy can be detected when the same SNP is found to be significantly
associated with multiple phenotypes. This method has shown great success in identifying
potential pleiotropy in several clinical genomics studies33,35,36,62,81,82. However, a limitation of
univariate analysis is that it tests only one trait at a time, so it cannot be a formal test of
pleiotropy. In contrast, bivariate analysis has been shown to have higher power over univariate
analysis by analyzing pairs of phenotypes simultaneously83. Furthermore, because bivariate
analysis can be structured to test the association of a trait with a variant, while adjusting for
another trait’s association with the variant, bivariate analyses can be constructed to formally test
pleiotropy, and extended to multivariate traits to perform sequential tests for pleiotropic
effects47,84. In this study, we used a bivariate analysis approach using summary-statistics from
univariate analysis to test the hypothesis of “joint association” of a SNP with a trait pair while
accounting for correlation in z-scores between the trait pair83. The alternative hypothesis here is
that at least one of the two traits is significantly associated with a SNP marker. This
implementation of bivariate analysis has suggested potential pleiotropy as well as hinted at
underlying disease-causing mechanisms in many recent studies66,85. Finally, multivariate analysis
is designed to test the joint association between genotype with multiple phenotypes in a single
regression model. Multivariate analysis has been shown to have increased power over univariate
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analysis in many scenarios, including when the genotype affects either a single phenotype or
multiple correlated phenotypes29,30. We chose MultiPhen45 to perform multivariate analysis
because of its ability to handle binary phenotypes as well as its high power, as demonstrated via
simulations29. In this paper, we refer to MultiPhen as multivariate analysis for the sake of
convenience. Again, here the alternative hypothesis is that at least one of many traits is
significantly associated with the SNP marker.
Since the “true” pleiotropic associations among cardiovascular diseases and neurological
disorders are largely unknown, we applied three types of widely used methods to characterize the
landscape of potential pleiotropy at genome-wide level27,86. To improve our confidence that the
list of potential pleiotropic variants obtained across all three methods reflect a single causal
variant instead of coincidental overlap, we performed statistical colocalization for these signals
with gene expression datasets across all 48 available tissues from the Genotype-Tissue
Expression (GTEx) consortium63. For instance, if a SNP colocalizes with an eQTL for traits A and
B, it means that the same SNP associates with both: (a) gene expression and trait A, (b) gene
expression and trait B. This can help us infer that the same SNP associates with both traits A and
B and is likely pleiotropic. We found that many of the potentially pleiotropic signals associated
with both disease groupings (diseases of the nervous and circulatory system) colocalized with
eQTLs from the GTEx consortium (especially on chromosome 22) indicating that gene expression
might be influencing risk of disease at those loci. This study is one of the first large-scale natural
data applications and evaluation of univariate, bivariate, multivariate and colocalization methods
in one comprehensive analysis. The overall study design is shown in Figure 3.1.

3.3

Methods
3.3.1

eMERGE network
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eMERGE Phase III Imputed Data

Genotype Quality Control

Phenotype Selection

Sample call rate ≥ 99%; SNP call rate ≥ 99%

European adults only (age ≥ 25 years)

Minor allele frequency ≥ 0.05; Imputation 'info' score > 0.4

Deﬁne phenotype based on ICD-9 category

Drop related individuals (pi_hat ≥ 0.25)

Number of cases ≥ 200

Remove variants in LD (r-squared > 0.5)

Association analyses, adjusted by age, sex, eMERGE site, 6PCs

Univariate Analysis

Multivariate Analysis

Bivariate Analysis

Test for colocalization of potential pleiotropic variants with eQTLs
across 48 tissues from the GTEx consortium33

Figure 3.1 Overview of the Analysis Plan
Figure 1. Overview of the analysis plan

In this study, we used data from the Electronic Medical Records and Genomics (eMERGE)
network Phase III. The eMERGE network is a National Human Genome Research Institute
(NHGRI) organized consortium to explore the utility of DNA biorepositories coupled with
Electronic Health Record (EHR) systems for large-scale genomic research. The eMERGE
network Phase III consists of 83,717 genotyped samples across multiple platforms that are
imputed to Haplotype Reference Consortium 1.1 reference in genome build 37 covering ~39
million genetic variants. There are seven eMERGE adult sites included in our study: Marshfield
Clinic Research Foundation, Vanderbilt University Medical Center, Kaiser Permanente
Washington/University of Washington, Mayo Clinic, Northwestern University, Geisinger, and
Harvard University.

3.3.2

Genotypic Data and Quality Control
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eMERGE Phase III imputed genotypic data were cleaned following the “best-practice” quality
control (QC) pipeline designed for imputed data87. We included genetic variants with genotype
call rate ³ 99% and sample call rate ³ 99%. We selected common variants with minor allele
frequency (MAF) ³ 0.05. To account for sample relatedness, we dropped one of each related pair
of individuals with pi_hat ³ 0.25 (obtained from identity-by-descent estimation using PLINK37). We
filtered out variants that had a linkage disequilibrium r2 greater than 0.5 using a 100kb sliding
window. We also filtered out the variants with a mean of imputation score less than or equal to
0.4. We further removed variants which have MAF difference greater than 0.1 compared to
European population from 1000 Genomes Project87. After genotypic QC assessment and LD
pruning, we had 54,942 unrelated individuals of European ancestry and 533,878 SNPs.

3.3.3

Phenotype Definition and Selection Criteria

Phenotype Definition
Cardiovascular and neurological phenotypes were defined using International Classification
of Diseases, Ninth Revision Clinical Modification (ICD-9-CM) billing codes. We selected 98 ICD9-CM codes from “Diseases of the circulatory systems” and “Diseases of nervous system and
sense organs” as our primary phenotypes. Table 3.1 presents the major disease groups and
corresponding ICD-9-CM codes. Of note, association analyses were performed using individual
ICD-9-CM codes to define case/control status, and we used broader major disease categories for
the purpose of presentation. The number of clinical visits per ICD-9-CM code per individual was
used to define case-control status for each ICD-9-CM code: a case would be assigned if an
individual had ³ 3 instances; a control would be assigned if an individual had zero instances; an
NA would be assigned if an individual had one or two instances35.
Phenotype Selection Criteria
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Our cohort comprised adults of European ancestry (age ³ 25 years) from eMERGE network
Phase III. We only used ICD-9-CM codes with more than or equal to 200 cases so as to increase
statistical power of association tests59. As a result, a total of 65 cardiovascular and neurological
ICD-9-CM based diagnoses and 43,870 individuals were included in our final round of association
analyses. Individuals who have both cardiovascular and neurological disease were counted as
cases for both. The sample size distribution of the 65 phenotypes is shown in Figure 3.2.
Table 3.1 Major Group and ICD-9-CM Category of Neurological Disorders and
Cardiovascular Diseases

Major Group

Circulatory
System

Nervous
System

3.3.4

Chronic rheumatic heart disease
Hypertensive disease
Ischemic heart disease
Diseases of pulmonary circulation
Other forms of heart disease
Cerebrovascular disease
Diseases of blood vessels
Other diseases of circulatory system
Inflammatory diseases of the central nervous
system
Hereditary and degenerative diseases of the
central nervous system
Pain
Disorders of the central nervous system
Disorders of the peripheral nervous system

ICD-9
Codes
393-398
401-405
410-414
415-417
420-429
430-438
440-449
451-459
320-327
330-337
338
340-349
350-359

Association Methods

Univariate Analysis
We performed univariate logistic regression using 65 ICD-9-CM based diagnoses with
533,878 variants. We adjusted logistic regression models for sex, age, eMERGE site, and the first
six principal components. We used PLINK 1.90 software37 to perform the first round of univariate
analysis because of its high computational efficiency. The logistic regression models converged
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for 33 out of 65 phenotypes. The major reason contributing to the non-convergence was the low
sample sizes corresponding to some of the sites when we adjusted for eMERGE site (7 levels) as
a categorical covariate. To address this, we used PLATO 2.1.038 to perform the second round of
logistic regression tests on the remaining 32 phenotypes with the same set of covariates as
before. Since PLATO implements an increased number of iterations compared to PLINK to find
the best solution for logistic models, the software achieved convergence for all the remaining
models. It should be noted that when both PLINK and PLATO converge, the results are
concordant; these tools have been extensively compared previously88.
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Figure 3.2 Sample Size Distribution for 65 ICD-9-CM Disease Categories

Bivariate Analysis
Bivariate analysis involved using summary-statistics (Z scores) from univariate analyses. We
modeled our bivariate analysis protocol (with modifications) on the one followed by Siewert et
al66. We first estimated mean and covariance of the Z scores obtained from univariate analyses
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for each of the 2,080 pairs of phenotypes using all the available LD-pruned SNPs. This was done
to ensure a null bivariate normal distribution of Z scores for each pair of phenotypes and to satisfy
the “independence” assumption for hypothesis testing. Subsequently, we applied a p-value
threshold of 0.005 on the univariate GWAS results and filtered out any SNPs that did not meet
this threshold. We also filtered out SNPs with MAF = 0.5 to remove ambiguity pertaining to which
allele was chosen as the referent allele in univariate analyses. Finally, we identified a list of
common SNPs and estimated a p-value for each of 2,080 “pairs” of phenotypes using a chisquared test with two degrees of freedom. Although we conducted a reduced number of tests, it
should be noted that we corrected for multiple comparisons using the original “unfiltered” SNP set
in order to control our type I error rate well.
Multivariate Analysis
We performed multivariate analysis using MultiPhen 2.0.2 R package45. MultiPhen analyzes
multiple phenotypes jointly by testing linear combinations of phenotypes against each SNP using
reverse ordinal regression. We adjusted for the same set of covariates as we did for univariate
tests. By default, MultiPhen excludes individuals with at least one NA out of 65 phenotypes.
Under this scenario, the power of association tests would be limited as there would only be 7,535
individuals in total with extremely low case sample size per phenotype. Since we applied the “rule
of three” to define a case, any person who had one or two instances of the occurrence of an ICD9-CM code was set to missing (N/A). Because we did not want to drop so many individuals, we
needed to fill in an alternative value for the N/A. For the purposes of multivariate analyses, these
missing values were replaced by 0.5 to retain comparable sample size with univariate and
bivariate analysis (sensitivity analyses on top significant SNPs yielded comparable results -- see
Discussion). These individuals are likely cases since they have the ICD code in their record one
or two times. A detailed evaluation of this replacement strategy will be conducted in the future to
determine if a more optimal imputation strategy exists. Finally, to increase computational
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efficiency of MultiPhen, we parallelized the runs by splitting the genome into chunks of 10Mb
each.

3.3.5

Statistical Correction

We implemented two Bonferroni correction calculation strategies to adjust for multiple testing
when comparing the statistical performance of three types of methods. The Bonferroni threshold
was calculated by dividing the level of significance by the number of tests. In the first strategy
(“method-specific Bonferroni”) we calculate Bonferroni threshold separately for each method. The
derived significant thresholds for univariate, bivariate, multivariate testing were 1.44x10-9
[0.05/65*533,878], 4.50x10-11 [0.05/(2,080*533,878)], and 9.37x10-8[0.05/533,878], respectively.
We used an overly conservative significance threshold for bivariate analyses due to potential nonindependence of tests (even after LD pruning). In the second strategy (“family-wise Bonferroni”)
we calculated the Bonferroni threshold based on the total number of tests across all three
methods. The derived significant threshold was 4.36x10-11
[0.05/(65*533,878+2,080*533,878+533,878)], and the criteria was applied across all three
methods. Again, this correction is overly conservative given the correlation across the tests and
methods but offers good control of the type I error rate.

3.3.6

Colocalization

Finally, we performed colocalization analysis to have greater confidence in our assessment
of pleiotropy. We first obtained a list of potentially pleiotropic variants that cleared the “family-wise
Bonferroni” multiple comparison threshold for univariate, bivariate and multivariate methods and
narrowed down this list to SNPs that were associated with at least one disease from both nervous
and circulatory systems. Finally, we ensured that for any given SNP, if one of the two traits in this
circulatory-nervous trait pair had a univariate p-value that did not meet the “family-wise
Bonferroni” threshold, it had a univariate -log10 p-value of at least 3. We termed the final list of
SNPs as our “lead” SNPs. To test if these signals were being influenced by gene expression as
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well as driven by the same underlying variant, we performed statistical colocalization analyses
using the “coloc” R package89 between these signals and eQTLs (across all 48 available tissues)
from the GTEx consortium63. We first obtained a 200KB window on either side of a “lead” SNP
and looked for whether the lead SNP (or one in close LD with it) was an eQTL in a given tissue. If
it was not an eQTL, that lead SNP was ignored. If it was an eQTL for a given tissue, we identified
the corresponding “eGene” and obtained summary statistics from GTEx for all gene-variant
associations in that 200KB window (either side). Note that we only chose the eGene that had the
smallest p-value for a given eQTL from GTEx. Finally, for each phenotype with which the lead
SNP is significantly associated, we performed statistical colocalization between the SNP and the
corresponding eQTL in that tissue. We set a coloc threshold of PP4/(PP3+PP4) > 0.8 to identify
pleiotropic signals that are strongly influenced by gene expression. Here PP4 refers to the
posterior probability that a single SNP associates with the phenotype as well as the gene
expression whereas PP3 refers to the posterior probability of having two independent SNPs
associate with either.

3.4

Results
3.4.1

Landscape of Univariate, Bivariate and Multivariate Associations
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Figure 3.3 Univariate, Bivariate and Multivariate Results A position-by-position
comparison of genetic associations for univariate, bivariate and multivariate methods using code
modified from Hudson R package (https://github.com/anastasia-lucas/hudson). The horizontal
axis represents genomic locations by chromosome and the vertical axis represents –log10(pvalue). Colors represent major disease groups of circulatory and nervous systems. The top plot
presents univariate results with p-value less than 0.01 in triangles and multivariate results that
passed “method-specific Bonferroni” threshold in black dots. The bottom plot present bivariate
analysis results in a two-colored circle, denoting the two phenotypes with which a variant is
associated with. The red lines in both plots are the “family-wise Bonferroni” threshold.
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Figure 3.4 Venn Diagram of the Number of SNPs Obtained at a “family-wise Bonferroni”

The landscape of univariate, bivariate, and multivariate association results is shown in
Figure 3.3. There is an overall similar trend of association signals for univariate and bivariate
analysis. We found that bivariate analysis identified more significant associations than univariate
analysis when the correlation between phenotypes was low (less than 0.4). From the bottom half
of Figure 3.3, we can see if the association signal from bivariate analyses comes from pairs of
circulatory, nervous or circulatory-nervous traits. Black dots in Figure 3.3 represent the variants
that passed “method-specific Bonferroni” significance from multivariate analysis. There are
scenarios in which there is no significant association from univariate/bivariate analyses but
significant results from multivariate analyses. Using “method-specific Bonferroni” threshold,
univariate, bivariate, and multivariate methods detected 124, 108, and, 107 unique statistically
significant SNPs, respectively; and there are 49 overlapping SNPs across three methods (data
not shown). The number of variants detected at the more stringent “family-wise” threshold is
given in Figure 3.4.

3.4.2

Variants associated with cardiovascular disease and neurological
disorders
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Among the 31 “family-wise Bonferroni” SNPs across all three methods, we obtained 9
unique variants that are significantly associated with at least one cardiovascular disease and one
neurological disorder from bivariate analysis that also “colocalized” with eQTLs across a host of
tissues with a coloc PP4/(PP3+PP4) probability threshold of at least 0.8. Table 3.2 shows a
comprehensive summary of these identified 9 variants. Our colocalization analyses revealed
whether there was a shared variant underlying our potentially pleiotropic signals and whether
gene expression may be influencing disease risk at these loci. For instance, the SNP at
chromosome 1 and position 36822024 colocalized with eQTLs in the same 35 tissues for
“Muscular dystrophies and other myopathies”, “Pain” and “Other conditions of the brain”
(neurological phenotypes) as well as “Heart failure”, “Essential hypertension”, “Cardiac
dysrhythmias” and “Hypotension” (cardiovascular phenotypes) (eGenes: EVA1B, TRAPPC3).
This means that rs10796883 influences 4 different cardiovascular disease categories, 3 different
neurological disease categories as well as gene expression for EVA1B and TRAPPC3 eGenes
across 35 different tissues. Likewise, the variant on chromosome 22 position 22947156
colocalized with eQTLs in 4 tissues (Brain-cerebellum, testis, transformed fibroblasts, small
intestine ileum) for 4 different neurological phenotypes as well as 9 other cardiovascular
phenotypes (eGenes: IGLV3-21, GGTLC2). Please refer to Appendix D for a complete list of
tissues in which each of the lead SNPs colocalizes with eQTLs.

Table 3.2 Potential Pleiotropic SNPs and Their Associated Disease Groups
NeglogP

NeglogP
Tissu

Circulatory NeglogP(UniSNP

variate)

Nervous NeglogP(Uni-variate)

(Bi-

(Multi-

e

variate)

variate)

count

eGenes

Muscular_dystrophies_and_other_myopath
1:36822024

Cardiac_dysrhythmias(11.305)

11.165
ies(4.921)

13.247

40

35

EVA1B, TRAPPC3

rs10796883

Other_conditions_of_brain(3.451)

12.030

35

EVA1B, TRAPPC3

Pain(4.151)

12.363

35

EVA1B, TRAPPC3

11.325

35

EVA1B, TRAPPC3

ies(4.921)

11.988

35

EVA1B, TRAPPC3

Pain(4.151)

11.452

35

EVA1B, TRAPPC3

ies(4.921)

10.699

35

EVA1B, TRAPPC3

Multiple_sclerosis(6.355)

18.112

8

Muscular_dystrophies_and_other_myopath
Essential_hypertension(9.125)
ies(4.921)

Muscular_dystrophies_and_other_myopath
Heart_failure(10.029)

Muscular_dystrophies_and_other_myopath
Hypotension(8.660)

HLA-DRB5, HLADRB9

Atherosclerosis(14.165)
HLA-DRB5, HLAParkinson's_disease(3.196)

6:32569056

15.097

11

DRB9

10.861
rs9270779

Occlusion_and_stenosis_of_pre
cerebral_arteries(6.355)

HLA-DRB5, HLAMultiple_sclerosis(5.913)

10.400

7

Other_peripheral_vascular_dise
ase(6.355)

DRB9

HLA-DRB5, HLAMultiple_sclerosis(7.442)

11.787

4

Muscular_dystrophies_and_other_myopath
ies(4.394)

DRB9

IGHV3-53,IGHV412.989

5

39, IGHV3-49

IGHV3-53,IGHV4Cardiac_dysrhythmias(11.322)
Other_conditions_of_brain(3.726)

12.420

5

14:106995720

39, IGHV3-49

IGHV3-53,IGHV418.291

rs7160440
Essential_hypertension(7.451)

Pain(6.297)

14.259

5

39, IGHV3-49

Pain(6.297)

10.610

1

IGHV3-49

IGHV3-53,IGHV4Heart_failure(9.038)

Muscular_dystrophies_and_other_myopath
ies(4.394)

39, IGHV3-49,
10.752

41

8

HOMER2P1

IGHV3-53,IGHV4Other_conditions_of_brain(3.726)

10.469

6

39, IGHV3-49

IGHV3-53,IGHV4Pain(6.297)

12.465

5

Pain(6.297)

11.623

5

ies(4.394)

11.832

5

Other_conditions_of_brain(3.726)

11.252

5

Hypertensive_chronic_kidney_d
isease(8.116)

39, IGHV3-49

IGHV3-53,IGHV4-

Muscular_dystrophies_and_other_myopath

39, IGHV3-49

IGHV3-53,IGHV439, IGHV3-49

IGHV3-53,IGHV4Hypotension(10.278)
39, IGHV3-49

IGHV3-53,IGHV4Pain(6.297)

13.004

5

0)

Pain(6.297)

11.224

1

Other_forms_of_chronic_ische

Inflammatory_and_toxic_neuropathy(14.21

mic_heart_disease(4.985)

1)

39, IGHV3-49

Illdefined_descriptions_and_comp
lications_of_heart_disease(7.61

22:22876236

rs361535

10.424
14.702

1

11.236

1

ies(3.773)

12.116

1

Other_conditions_of_brain(3.328)

11.738

1

Pain(5.622)

13.348

Inflammatory_and_toxic_neuropathy(3.011
)

Muscular_dystrophies_and_other_myopath
Cardiac_dysrhythmias(10.930)

22:22947156
28.019

1

rs2097594
Inflammatory_and_toxic_neuropathy(3.011
)

Cardiomyopathy(12.330)

12.818

2

Muscular_dystrophies_and_other_myopath

GGTLC2

IGLV3-21,

ies(3.773)

13.768

2

GGTLC2

Other_conditions_of_brain(3.328)

13.507

1

GGTLC2

42

Pain(5.622)

15.503

2

GGTLC2

ies(3.773)

11.380

2

BCRP4

Other_conditions_of_brain(3.328)

10.968

Pain(5.622)

12.386

19.807

2

GGTLC2

ies(3.773)

20.963

3

GGTLC2

Other_conditions_of_brain(3.328)

21.000

2

GGTLC2

Pain(5.622)

22.553

2

GGTLC2

ies(3.773)

10.760

2

GGTLC2

Pain(5.622)

12.119

2

GGTLC2

ies(3.773)

10.883

2

GGTLC2

Other_conditions_of_brain(3.328)

10.491

2

GGTLC2

Pain(5.622)

12.026

2

GGTLC2

10.863

2

GGTLC2

ies(3.773)

11.703

2

GGTLC2

Other_conditions_of_brain(3.328)

11.478

2

GGTLC2

Pain(5.622)

13.385

2

GGTLC2

Muscular_dystrophies_and_other_myopath

Essential_hypertension(10.187)

Inflammatory_and_toxic_neuropathy(3.011
)

Muscular_dystrophies_and_other_myopath
Heart_failure(20.621)

IGLV3-21,

Muscular_dystrophies_and_other_myopath
Hypertensive_chronic_kidney_d
isease(9.331)

Muscular_dystrophies_and_other_myopath

Hypotension(9.778)

Inflammatory_and_toxic_neuropathy(3.011
)
Illdefined_descriptions_and_comp
lications_of_heart_disease(10.6
65)

Muscular_dystrophies_and_other_myopath

Other_diseases_of_endocardium

Inflammatory_and_toxic_neuropathy(10.34

(10.340)

0)

11.032

43

Muscular_dystrophies_and_other_myopath
ies(10.340)

11.844

Other_conditions_of_brain(10.340)

11.617

Pain(5.622)

13.627

Inflammatory_and_toxic_neuropathy(11.87
3)

Other_forms_of_chronic_ische
mic_heart_disease(11.873)

11.335

Muscular_dystrophies_and_other_myopath
ies(11.873)

12.690

Other_conditions_of_brain(11.873)

12.530

Pain(5.622)

14.168

KIAA1671,
Inflammatory_and_toxic_neuropathy(4.159

SGSM1, CRYBB2,

)

10.817

11

Organic_sleep_disorders(4.166)

10.687

1

CRYBB3, IGLL3P

Cardiac_dysrhythmias(9.528)
IGLL3P

KIAA1671,
Pain(4.590)

11.247

6

IGLL3P

22:25420792
40.505

KIAA1671,

rs13056641
SGSM1, CRYBB2,
Inflammatory_and_toxic_neuropathy(4.159

CRYBB3, IGLL3P,

)

12.620

16

BCRP3

Organic_sleep_disorders(4.166)

12.521

1

IGLL3P

Essential_hypertension(12.162)

KIAA1671,
Pain(4.590)

13.284

7

IGLL3P

KIAA1671,
Angina_pectoris(3.067)
Pain(13.338)

22:25436904

15.015

7

SGSM1, IGLL3P

58.239
rs1040421

KIAA1671,
Atherosclerosis(5.075)

Pain(13.338)

15.580

44

8

SGSM1, IGLL3P

KIAA1671,
Cardiac_dysrhythmias(11.931)

Pain(13.338)

20.872

7

SGSM1, IGLL3P

KIAA1671,
Cardiomyopathy(4.939)

Pain(13.338)

15.904

8

Conduction_disorders(5.764)

Pain(13.338)

16.372

5

Essential_hypertension(10.303)

Pain(13.338)

19.175

8

Heart_failure(7.101)

Pain(13.338)

17.129

8

SGSM1, IGLL3P
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KIAA1671,
SGSM1, IGLL3P
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Hypertensive_chronic_kidney_d
isease(7.426)

SGSM1, IGLL3P
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Pain(13.338)

17.404

8
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Hypotension(6.693)
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16.037

4

Other_diseases_of_endocardium
(5.845)

SGSM1, IGLL3P

KIAA1671,
Pain(13.338)

16.677

4

Pain(4.966)

12.443

19

11.884

9

SGSM1, IGLL3P

22:28250172
Cardiac_dysrhythmias(10.517)
rs1997739

ZNRF3, TTC28-

22.064

Hereditary_and_idiopathic_peripheral_neu
ropathy(3.049)

FBXO7, SLC5A4-

Inflammatory_and_toxic_neuropathy(3.958
)

AS1

AS1

FBXO7, SLC5A412.254

2

AS1

Cardiac_dysrhythmias(11.280)
22:33079917

Mononeuritis_of_lower_limb_and_unspeci

FBXO7, SLC5A423.601

fied_site(3.153)

rs5749490

12.242

2

AS1

FBXO7, SLC5A4Pain(8.424)

16.011

9

Hypertensive_chronic_kidney_d
isease(6.449)

AS1

FBXO7, SLC5A4Pain(8.424)

12.064

45

9

AS1

Hypertensive_heart_disease(4.1
91)

FBXO7, SLC5A4Pain(8.424)

10.592

10

AS1

FBXO7, SLC5A4Hypotension(8.197)

Pain(8.424)

12.959

3

AS1

Notes: We left as missing in the table any eGene (Ensembl gene ID from GTEx) that did not have an HGNC symbol counterpart.

3.5

Discussion
In this study, we conducted EHR-based univariate, bivariate, and multivariate analyses on

43,870 adults of European ancestry from the eMERGE network using 65 cardiovascular and
neurological ICD-9 disease categories. The aim of this study was to detect pleiotropic genetic
variants that influence diseases of the circulatory and nervous systems. We also evaluated the
performance of three types of methods for detecting pleiotropy.
We observed 79, 108, and, 58 unique variants, respectively that were detected by univariate,
bivariate, and multivariate methods and 31 that overlapped among the three methods using a
“family-wise Bonferroni” significance threshold. Univariate analysis suggests direct association
between genetic variant and phenotype; bivariate association can offer insights into whether a
variant is associated with a pair of phenotypes, whereas multivariate analysis is powerful in
detecting if a variant is associated with multiple phenotypes. We took the intersection of the
significant genetic variants across the three methods as our list of potential pleiotropic variants.
Our colocalization analyses revealed 9 SNP variants associated with at least one disease from
both the nervous and circulatory systems that cleared the “family-wise Bonferroni” threshold for
multivariate and bivariate analyses. Since we were looking at trait pairs here, we ensured that at
least one of the two traits had a univariate p-value that cleared the “family-wise Bonferroni”
threshold while the other trait had a univariate -log10 p-value of at least 3. Note that we
conducted sensitivity analyses for MultiPhen on identified potentially pleiotropic variants in Table
3.2 when missing values were imputed with 0 and 1 (i.e. treated as controls or cases) in addition
to 0.5 and observed no change in significance. To cross-check overlap between methods, we
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also performed multivariate analysis restricted to a pair of bivariate significant traits for the 9
potentially pleiotropic variants in Table 3.2 and found 100% consensus between bivariate and
multivariate methods. These 9 variants showed strong evidence of colocalization with eQTLs
across a host of tissue types (see Appendix D) from the GTEx consortium63, especially on
chromosome 22.
Our results replicated previous association signals as well as detected novel associations.
SNP at chromosome 6 position 32569056 (rs9270779) has been directly implicated in autonomic
nervous system and has been shown to be associated with heart rate response to exercise in
females suggesting it could be pleiotropic for the two disease groupings of interest90. Also, the
corresponding eGenes for this SNP, HLA-DRB5 and HLA-DRB9 from colocalization analysis
have been previously shown to be associated with multiple sclerosis. Among the 31 total SNP
hits, the one at chromosome 19 position 45416741 (rs438811) is correlated with rs445925
(r2=0.341), which has been shown to be clinically relevant to cardiovascular phenotypes90. This
SNP is also located in the APOC1/APOE region, which has been shown to be associated with
Alzheimer’s disease65. Among novel potential pleiotropic variants identified by all three methods
and colocalization analysis, 6 out of 9 variants locate on chromosome 22, suggesting its potential
crucial contribution to the link between cardiovascular and neurological diseases. In particular,
the eGene FBXO7 has been associated with multiple sclerosis65 as well as heart disease65. As
part of future work, we will conduct pathway analyses or conditional analyses to have confidence
in a singular pleiotropic association or shared biology between these disease groupings.
The limitations of this study are that (1) using only ICD-9-CM codes instead of both ICD-9CM and ICD-10-CM codes may have reduced the number of cases in our data; (2) the use of
disease category instead of disease code as phenotype might have reduced the specificity of
detected associations. We are planning to incorporate ICD-9-CM and ICD-10-CM codes to define
primary phenotypes and examine disease heterogeneity in the future; (3) sample size
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considerations led to some diagnosis codes being left out of analyses; (4) given our very
conservative multiple comparison thresholds, we have likely reported only a fraction of all
potential pleiotropic signals, leading to type II errors, and (5) we were unable to investigate how
many additional associated variants obtained using bivariate analyses in comparison to univariate
and multivariate were “true positives”. One way to investigate this would be to test for statistical
colocalization on top of bivariate analysis hits66. However, this necessitates that summary
statistics be obtained from independent datasets which was not the case with our data.
Replication of these signals in independent cohorts in future can help us address this limitation.
In summary, we provide a framework for future pleiotropy analyses in EHR data. Our work
expands the pleiotropy detection framework from univariate methods (e.g. PheWAS) to bivariate
and multivariate methods in large-scale real-world EHR data to detect a broader net of potentially
pleiotropic signals across cardiovascular and neurological disorders. We also utilize colocalization
analyses to enhance our understanding of the influence of gene expression on these potentially
pleiotropic variants and consequently on disease risk. In future, we will also try to replicate the
partially overlapping SNP signals in independent cohorts.
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CHAPTER 4 Large-scale genomic analyses reveal insights into pleiotropy across
circulatory system diseases and nervous system disorders
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4.1

Abstract
Clinical and epidemiological studies have shown that circulatory system diseases and

nervous system disorders often co-occur in patients. However, genetic susceptibility factors
shared between these disease categories remain largely unknown. Here, we characterized
pleiotropy across 107 circulatory system and 40 nervous system traits using an ensemble of
methods in the eMERGE Network and UK Biobank. Using a formal test of pleiotropy, five
genomic regions demonstrated statistically significant evidence of pleiotropy. We observed
region-specific patterns of direction of genetic effects for the two disease categories, suggesting
potential discordant and concordant pleiotropy. Our findings provide insights into the relationship
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between circulatory system diseases and nervous system disorders which can provide context for
future prevention and treatment strategies.

4.2

Introduction
Circulatory system diseases and nervous system disorders have a significant impact on

mortality worldwide. Because of the distinct disease manifestations, diseases in these categories
have long been diagnosed, treated, and studied independently. However, for decades, clinicians
and researchers have noted a link between circulatory system diseases and nervous system
disorders. For instance, it is clear that cardiac pathologies can be produced as a result of
neurological illness91. Heart failure is a potential risk factor for Alzheimer’s disease92 and occurs
more than twice as often in Parkinson’s disease patients compared to non-Parkinson’s disease
patients93. However, the genetic variants influencing both disease categories are largely
unknown.
One of the potential genetic links can be via pleiotropy, a phenomenon by which a gene or a
genetic variant influences more than one phenotypic trait20. Pleiotropy has long been recognized
in model organisms11, and its ubiquitous role has recently been appreciated in the human
genome—90% of genome-wide association study (GWAS) loci are pleiotropic21,94. The definition
of pleiotropy in this manuscript refers to ‘statistical pleiotropy.’ which describes a genetic variant
that is statistically associated with more than one trait21. Large-scale biobanks, coupled with
Electronic Health Records (EHRs), offer unprecedented opportunities to study pleiotropy.
Nevertheless, most studies of pleiotropy in biomedical data are solely inferred from GWAS
studies21,76,94,95 in multiple independent datasets. For instance, a global overview of pleiotropy
across phenotypes with high disease prevalence has been demonstrated using GWAS summary
statistics21, highlighting the extent of pleiotropy across broad disease categories. However,
genetic variants that contribute to a wide spectrum of diseases (including the less common ones)
across specific disease categories have not been extensively studied.
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Methods for detecting pleiotropy can be broadly grouped into univariate and multivariate
categories. Univariate methods test the association between one genetic variant and one
phenotype per statistical model. Phenome-wide association studies (PheWAS) are among the
most commonly used univariate methods that examine the impact of genetic variants across a
broad range of phenotypes using univariate regression models34. The application of PheWAS has
uncovered novel potential pleiotropy using EHR phenotypes in many prior studies35,36,62,81.
Additional univariate methods in the literature also refer to a combined analysis of summary
statistics obtained from multiple GWAS studies4-10. Multivariate methods, or multi-trait joint
methods, refer to the inclusion of two or more phenotypes in the association test in the same
statistical model20. Multivariate methods have demonstrated increased power for detecting
pleiotropy but have not been widely applied on large-scale natural biomedical datasets. In this
study, we used MultiPhen45 as our multi-trait joint analysis method as it is designed for binary
phenotypes and has shown sufficient statistical power96. MultiPhen analyzes multiple phenotypes
simultaneously by testing the linear combination of phenotypes with the genotype using an
ordinal regression model. In general, multivariate methods are more powerful than combining
univariate GWAS summary statistics80. Since no single method can detect all types of genotypephenotype relationships in natural biomedical data, it has been suggested to apply both univariate
and multivariate methods80 and to view them as complementary approaches41. This is the
strategy we adopted in this study.
In this study, we aimed to characterize pleiotropy specifically across circulatory system
diseases and nervous system disorders. We have applied genome-wide PheWAS and MultiPhen
analyses on 43,015 European adults from the eMERGE network, followed by a systematic
replication analysis in 295,423 European-ancestry participants from the UK Biobank (UKBB)
(Appendix B Fig. S1). This effort yielded a comprehensive comparison of the characteristics of
applying univariate and multivariate methods on independent biobank datasets. To investigate
pleiotropy, we further performed a formal statistical test of pleiotropy, which pinpoints precisely
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which specific phenotypes show evidence of pleiotropy via performing multivariate analyses
iteratively using a method called Pleio47. Through these analyses, we have provided evidence to
explain the relationship between circulatory system diseases and nervous system disorders that
can be characterized as pleiotropic, recognizing that we observed both concordant and
discordant pleiotropy between these disease categories.

4.3

Methods
4.3.1

Biobank datasets

The eMERGE Phase III dataset contains high-density genotype data for 99,185 subjects
coupled with longitudinal electronic health records (EHRs). Subjects were genotyped across 78
genotype array batches and imputed to ~40 million variants97. Details of the imputation have been
discussed elsewhere97. Among 12 contributing study sites across the United States, we have
included six adult study sites in this study: Marshfield Clinic Research Foundation, Kaiser
Permanente/University of Washington, Vanderbilt University Medical Center, Mayo Clinic,
Geisinger, and Partners Healthcare. The eMERGE dataset was used for discovery analysis.
UKBB cohort release version 2 has deep genetic and phenotypic data on ~500,000
individuals across the United Kingdom. Individuals were genotyped on two similar types of
genotype array across 106 batches and imputed to 96 million variants24. eMERGE network and
UKBB have the same genome build, GRCh37/hg19. The replication analyses in UK Biobank was
performed on the statistically significant SNPs from eMERGE (p£10-4 described more below) that
were also present and passed QC in the UK Biobank dataset.

4.3.2

Phenotype Definitions

The phenotypes were defined based on the International Classification of Diseases (ICD)
diagnosis codes extracted from the EHR. Since the disease coding practices and regulations
differ between the US and the UK, the composition and distribution of diagnosis codes are
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different. To maximize the phenotypic information, we have accordingly applied different, yet
complementary strategies to the two datasets.
Since ICD-10 codes have added specificity compared to ICD-9 codes, we chose to convert
ICD-10 codes to ICD-9 codes. For UKBB, we have only included individuals who had ICD-10
occurrences to retain its original collection of disease codes and because fewer data were
available for ICD-9 codes in the UKBB. Because the disease diagnosis codes in UKBB were
curated and represented by the presence or absence of a certain ICD codes, this information was
used to define case status; this means that if a person has a certain ICD-10 code present in the
EHR, that person would be assigned as a “case” for that phenotype. If the person did not have
that diagnosis code, he/she would be assigned as a “control”. As for eMERGE, we have
converted ICD-10-CM to ICD-9-CM codes using a combination of general equivalence
mappings98 and manual review. Because eMERGE offers longitudinal measures on diagnosis
codes, we have applied a “rule of three” on ICD-9-CM codes to define case status. This means
that if a person had three or more occurrences of a certain ICD-9-CM code in their EHR on
different clinic visits, that person would be assigned as a “case”. If a person had either one or two
occurrences of a particular ICD-9-CM code, an “NA” status would be assigned. Finally, if a person
did not have any occurrence of a particular ICD-9-CM code, a “control” status would be assigned
for that phenotype. This approach was used to assign case status for all available phenotypes.
One general caveat of EHR data in the eMERGE dataset is that the absence of certain disease
diagnosis code for some individuals does not equal the absence of the disease, as the patients
might get the medical care at another institution thus may not present in our datasets. This would
bias results toward the null, thus we don’t expect that this impacted our study in a substantial
way.

4.3.3

Genotype Quality Control
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For the eMERGE dataset, we dropped imputed genotype array batches with a mean Rsquared of imputation score < 0.3 as well as batches that had fewer than 50 samples97. We also
excluded genetic variants with a mean R-squared of imputation score < 0.3 calculated across
batches. We used a combination of self-reported European ancestry and principal component
analyses to extract individuals of European ancestry for inclusion. We applied genotype call rate
and sample call rate of ³ 99% and selected genetic variants with a minor allele frequency (MAF)
³ 0.01. We excluded SNPs with Hardy-Weinberg Equilibrium exact test p-values below 1´10-10.
We dropped related individuals that were second-degree relatives or closer with pi-hat larger than
0.25. Since our phenotypes of interest are the late-onset nervous system and circulatory system
diseases, we selected European ancestry adult individuals only with age ³ 25 years old. After
QC, there are 43,015 individuals and 7,629,801 SNPs included for analysis. We generated
principal components (PCs) for the final set of individuals using high quality, common SNPs (with
MAF ³ 0.05 and R-squared ³ 0.7)97 and adjusted for the first two PCs in all subsequent
association analyses based on the proportion of variance explained by the PCs. The projection of
the first two PCs and the proportion of variance explained by the PCs are provided in Appendix B
Fig. S4.
For quality control in the UKBB, we largely followed the protocols of a previous publication24
and utilized information provided as part of the data release. We excluded poor quality individuals
according to previous publication24. We dropped related individuals that were second-degree
relatives or closer with pi-hat larger than 0.25. We have also removed individuals who had sex
mismatches between self-reported and genetically inferred sex. Genetic variants with an
imputation info score < 0.3 and MAF < 0.01 were excluded. European ancestry individuals were
extracted using a combination of self-reported white British ancestry and principal component
analyses24. Since age at recruitment for the UKBB cohort is 40-6924, we did not apply any age
filter. After quality control, there were 377,921 individuals and 9,505,767 SNPs available for
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analysis. After applying the above-described phenotype filtering, there were 295,423 individuals
from UKBB that had ICD-10 codes documented in their EHR data. This was the final sample size
for UKBB used in all subsequent analyses. We used the first 20 PCs that were provided by the
data release for the association analyses24.

4.3.4

Association Analyses

PheWAS
We performed genome-wide PheWAS for 43,015 eMERGE individuals and 7,629,801 SNPs
across a total of 147 circulatory system diseases and nervous system disorders via PLINK37 v1.9
software. Logistic regression models were adjusted by age, sex, eMERGE study site, and the first
two PCs. There were about 1 billion association tests conducted in this genome-wide PheWAS.
Out of the 147 phenotypes evaluated, nine phenotypes did not converge using PLINK due to the
small case number per study site. To address this, we performed the same logistic association
tests for those nine phenotypes using PLATO88. The larger number of default iterations in PLATO
successfully resolved the non-convergence issue. From approximately 1 billion association tests,
145,194 SNPs were statistically significant with a p-value ≤ 1´10-4 from either univariate and/or
multivariate analyses in eMERGE; these SNPs were selected for replication in UKBB. From this
set of SNPs, we performed PheWAS on 134,363 SNPs that passed quality control in the UKBB
dataset (10,831 of the significant SNPs from eMERGE were either dropped during QC or were
not available in UKBB). To address the ambiguity of SNPs with MAF near 0.5 in each of the two
datasets, we have flipped the direction of genetic effect sizes for 552 SNPs in UKBB that had (a)
MAF ³ 0.4 and (b) reference and alternative alleles switched in eMERGE network. In the UKBB
PheWAS, the following covariates were included for adjustment: age, sex, genotyping array, and
the first 20 PCs. For UKBB we also re-ran the associations with Townsend Deprivation Index
(TDI) as an additional covariate; the results did not change and since we do not have TDI for
eMERGE, we did not include it in the results reported.
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Multi-trait joint analysis
For multi-trait joint analyses, we used the MultiPhen45 R package to perform our analyses.
MultiPhen tests the linear combination of phenotypes by treating SNPs as response variables,
and phenotypes as predictor variables. It uses a proportional odds regression model to test for
statistical association. As was done for the PheWAS described above, we performed a genomewide MultiPhen analysis for eMERGE. The MultiPhen analyses in UKBB were performed the
same set of 134,363 SNPs (see PheWAS Method section). The same set of covariates described
in PheWAS Methods section were used in the MultiPhen analyses. All of the phenotypes
(including both circulatory and nervous system diseases) have been jointly analyzed in the
MultiPhen model. Because the current version of MultiPhen is not able to deal with NA
phenotypes, we imputed NA with 0.5 for the eMERGE phenotypes. The presence of an NA
indicates that a person had at least one instance of the ICD9-CM code in their EHR. This leads to
a greater likelihood that the person is a case rather than a control. In a previous pilot study, we
performed a sensitivity analysis on significant SNPs to evaluate this imputation method in
eMERGE; we found that it retained the same level of statistical significance as imputing to 0 or
158. Thus, based on our previous study, we kept the imputation of 0.5 for NA. The time and
memory for running MultiPhen increases with the sample size and the number of phenotypes. In
order to run analyses efficiently, we parallelized our operations by dividing the genome into
subset files (2000 variants per file for eMERGE and 500 variants per file for UKBB).
Sequential multivariate analysis
To evaluate which associations show evidence of pleiotropy, the next step in our study was
to perform a formal test of pleiotropy. We selected the sequential multivariate analysis using the
‘pleio’ R package47 to perform this test for pleiotropy. ‘Pleio’ extended the multivariate analysis
framework to sequentially test the null hypothesis that k+1 traits are associated with the genotype
given that k traits are associated47. It characterizes the exact traits that are associated with the
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SNP while accounting for the correlation among the traits. Note that the alternative hypothesis for
general multivariate framework is that there is at least one phenotype being associated with the
genotype, i.e., we would not know the exact associated traits. We have conducted sequential
multivariate analysis on a set of 607 SNPs. This set was derived from the list of SNPs that met a
p-value threshold of 1x10-4 in eMERGE PheWAS and/or MultiPhen AND replicated in UKBB at a
p-value threshold of 1x10-4 in the UKBB PheWAS and/or MultiPhen. The same set of covariates
has been adjusted as described in the PheWAS Methods section. Since the number of sequential
tests increases drastically as the number of associated phenotypes increases, we have
performed our analyses on a subset of selected phenotypes. We selected this set of phenotypes
based on the univariate PheWAS analysis results. Each phenotype that had a PheWAS p-value <
0.01 for each SNP was selected for the sequential multivariate test. The set of phenotypes tested
can be different between the two datasets due to differences in univariate p-value for each SNPphenotype pair. The p-value significance threshold for rejecting the null hypothesis in the
sequential multivariate model was set at 1´10-8, the same as the genome-wide significance level.
This threshold was chosen due to the same number of association tests being potentially
performed using a general multivariate framework and in a univariate GWAS study. In other
words, the output phenotypes of ‘pleio’ would need to have a multivariate joint significance of less
than 1´10-8 to reject the null hypothesis.

4.3.5

Conditional Analyses

We performed conditional analyses on the whole set of phenotypes that are associated with
each identified pleiotropic SNP (see Results). We evaluated all pairwise combinations of the
phenotypes, with one as the dependent variable while another one as independent variable.
Specifically, we applied logistic regression on dependent variable while treating another
phenotype as an independent variable, along with previously mentioned covariates. We
evaluated the impact of adjusting for another phenotype on the significance of the SNP by
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measuring the log odds ratio of the p-value from two events: conditional analysis and
independent analysis (without adjusting for another phenotype). The form of log odds ratio is
), where pc denotes the p-value from the conditional analysis and p denotes the pvalue from the independent analysis. We plotted the mean of log odds ratio (across SNPs in the
same region) in heatmap, where the phenotype on each row denotes the dependent variable and
each column denotes the phenotypes that were being adjusted in the conditional analysis
(Appendix B Fig. S6). When the log odds ratio deviates from zero, it suggests that adjusting for
that particular phenotype (independent variable) changes the significance of the association with
the other phenotype (dependent variable), thus suggesting that the association (for certain SNP)
between one phenotype is related to another phenotype. On the other hand, if the value is close
to zero, it’s likely that the SNP is independently associated with both phenotypes rather than
affect one trait through influencing the other one.

4.3.6

Case Overlap Calculations

We obtained the number of overlapping cases between pairwise phenotypes of identified
pleiotropy. Since the case sample size varies among phenotypes due to different disease
prevalence, we plotted the proportion of overlapping cases, calculated as the number of
overlapping cases divided by the total case sample size. We demonstrated this distribution in
heatmap, where the phenotype in the row refers to the total case sample size used as the
denominator when calculating the proportion (Appendix B Fig. S6).

4.3.7

Sex-stratified Analyses

The rationale of sex-stratified analyses is the same as the combined analyses except that
we stratified the analyses by sex in the eMERGE and UKBB. There are 22,129 female and
20,886 male individuals in the eMERGE; there are 161,296 female and 134,127 male individuals
in the UKBB. We performed PheWAS followed by sequential multivariate analyses to
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characterize pleiotropy. The covariates that were adjusted were the same as before except that
‘sex’ was excluded. The p-value threshold was also the same: the tested phenotypes in
sequential model were selected using a PheWAS p-value of 0.01, and the p-value threshold for
sequential multivariate testing is 1´10-8. We did not apply case number filtering in sex-stratified
analyses.

4.3.8

Data Visualization

The Hudson R package (https://github.com/anastasia-lucas/hudson) was used for comparing
association results from eMERGE and UK Biobank (Figure 4.1 & Figure 4.3). The Venn diagram
(Figure 4.2 & Figure S2B) was created by UpSetR181. The demonstration of pleiotropy among
disease categories were presented in circos plots182 (Figure 4.5, Appendix B Figure S5). Regional
LD plots were generated by LocusZoom183. The heatmap were generated using heatmap.2
function in ‘gplots’ R package184.

4.4

Results
4.4.1

Phenotypic Characterization

The eMERGE Phase III dataset consists of 99,185 subjects coupled with longitudinal EHR
data from the United States. The UKBB has genotypic and phenotypic data on 487,409
individuals from the United Kingdom. Our phenotypes of interest are a comprehensive set of
circulatory system diseases and nervous system disorders.
The phenotypes are defined by utilizing the International Classification of Diseases (ICD)
diagnosis codes obtained from the EHR. Because of the differences in disease coding practices
and regulations between the US and the UK, the composition of ICD codes differs between the
two datasets. The eMERGE network has mostly (~82%) ICD-9-CM codes, while the UKBB has
predominantly (~98%) ICD-10 codes. However, to our current knowledge, there is no available
official equivalence mapping that maps ICD codes between the UK and the US, given that the US
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uses its own national variation of ICD codes (known as ICD-CM). To address this for our
replication study design, we collected the ICD codes from the official website in three broad
categories: ‘mental disorders’, ‘disease of the nervous system’, and ‘disease of circulatory
system’, used the disease categories provided by ICD to assign the ICD-9-CM and ICD-10 codes
into their respective categories, and then manually curated a common list of phenotypes that are
present in both eMERGE and UKBB.
We excluded phenotypes based on the following criteria: 1. Disease that was secondary to
environmental or comorbid causes such as drug or injury; 2. Childhood-onset developmental and
psychiatric disorders; and 3. Diseases mainly occurring in organs other than heart and brain
(such as the limbs). We applied a minimum case number threshold of 200 to ensure adequate
statistical power of the association tests59. In this study, we use the term “nervous system
disorders” to refer to mental disorders and diseases of the nervous system99. In total, we curated
40 and 25 nervous system diseases in eMERGE and UKBB, respectively; 107 and 77 circulatory
system diseases in eMERGE and UKBB, respectively (Appendix A Table S1). These phenotypes
are categorized into seven groups of circulatory system diseases and seven groups of nervous
system disorders (Appendix A Table S1).

4.4.2

Discovery and Replication of Univariate and Multivariate Associations

After quality control, genome-wide PheWAS and MultiPhen analyses were performed on
43,015 European ancestry adults and 7,629,801 common SNPs across 147 phenotypes in the
eMERGE network. A formal systematic replication analyses was conducted in UKBB on 134,363
genetic variants that had an exploratory p-value significance of ≤ 1´10-4 from analyses in
eMERGE dataset (and passed QC in the UKBB dataset). The use of an exploratory p-value
threshold enables studies of genetic variants beyond the most significant signals that may
otherwise be potentially informative62.
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From PheWAS results for eMERGE and UKBB (Figure 4.1), we found that the top
association signals from eMERGE analyses are reproducible in the UKBB replication dataset,
many of which serve as positive controls as they were discovered in previous studies in the
literature. For instance, we observed that SNPs located on chromosome 4q25 are significantly
associated with atrial fibrillation in eMERGE and replicated in UKBB. In particular, we replicated a
previously reported SNP rs2200733 near PIXT2 gene (eMERGE p-value: 5.898´10-37, UKBB pvalue: 7.112´10-142) that was shown to be significantly associated with atrial fibrillation among
individuals of European ancestry100. We also identified SNPs near the APOE gene at 19q13.32 to
be associated with Alzheimer's disease and dementia; of these, we replicated a previously
reported SNP, rs429358, as our top SNP (discovery eMERGE p-value: 1.604´10-74, replication
UKBB p-value: 6.327´10-54) associated with Alzheimer's disease101. Similarly, we found a
previously-detected association between SNP rs1333049 near CDKN2B-AS1 (discovery
eMERGE p-value: 6.016´10-22, replication UKBB p-value: 7.982´10-77) and coronary artery
disease102, and found SNPs in the HLA region to be highly associated with multiple sclerosis103.
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Figure 4.1 Landscape of PheWAS Results.
A position-to-position comparison of PheWAS results between eMERGE and UKBB. X-axis
stands for the genomic position across 22 chromosomes; Y-axis stands for the -log10(p-value).
eMERGE PheWAS was performed genome-wide as the discovery analysis. UKBB PheWAS
included on the SNPs that passed p £ 1x10-4 in eMERGE as the replication analysis. The
direction of each triangle indicates the direction of genetic effect. Colors denote various disease
groups. The assignment of ICD codes to disease groups can be found in Appendix B Table S1.
The red line indicates the GWAS significance threshold p-value of 1´10-8. To reduce the margin
induced by the extremely small p-values, we have collapsed SNPs with p-value less than 1´10-95
into one overlapping triangle indicated by an asterisk on chromosome 4 for UKBB.

In the UKBB replication dataset, we observed lower p-values (high significance levels) for
many genetic regions that showed moderate significance (1´10-8 £ p-value £ 0.001) in the
eMERGE dataset. For example, SNPs on chromosome 4 that were moderately associated with
essential hypertension in the eMERGE network demonstrated a strong significance of association
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in the UKBB. Similar noticeable association signals were observed in UKBB across the genome
(Figure 4.1). Overall, the UKBB PheWAS replicated 7,607 SNPs (Figure 4.2: 4433 + 2517 + 607
+ 50 = 7607) from the discovery eMERGE PheWAS (out of 134,363 SNPs that were evaluated in
the UKBB replication PheWAS) using an exploratory p-value threshold (Figure 4.2).
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Figure 4.2 Comparison of the Number of Significant SNPs Identified by PheWAS and
MultiPhen from eMERGE and UK Biobank. The p-value threshold is 1´10-4. The SNPs are
counted when they suggest significant associations with at least one phenotype. For PheWAS,
we included the SNPs when its minimum p-value among phenotypes passed the threshold.
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The landscape of MultiPhen results is shown in Figure 4.3. Most of the strong association
signals that were observed in PheWAS (Figure 4.1) were also significant in MultiPhen analyses.
As with the PheWAS results, MultiPhen identified previously known SNPs in both datasets,
including the previously-mentioned rs2200733 (eMERGE multi-trait joint p-value: 8.305´10-16,
UKBB multi-trait joint p-value: 5.873´10-82), rs429358 (eMERGE multi-trait joint p-value:
3.137´10-48, UKBB multi-trait joint p-value: 3.888´10-49) and rs1333049 (eMERGE multi-trait joint
p-value: 1.309´10-15, UKBB multi-trait joint p-value: 6.208´10-62). Compared to PheWAS results
(Figure 4.1), the overall significance level was lower in MultiPhen results (Figure 4.3). To extract
how many unique SNPs were significant in the discovery and replication analyses using
univariate (PheWAS) and multivariate (MultiPhen) approaches, we created an UpSet181 plot
(Figure 4.2). For example, in eMERGE, 1,093 SNPs passed the exploratory p-value threshold
(1x10-4) in both PheWAS and MultiPhen analyses (Figure 4.2: 607 + 436 + 50 = 1093), whereas
there were 54 SNPs that only showed significance in eMERGE MultiPhen analyses (Figure 4.2:
51 + 2 + 1 = 54) (Figure 4.2). For UKBB, there were 3,125 SNPs that passed the replication pvalue threshold (1x10-4) in both PheWAS and MultiPhen results (Figure 4.2: 2517 + 607 +1 =
3125) and 26 SNPs were only identified by MultiPhen (Figure 4.2).
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Top: eMERGE (43,015 individuals), Bottom: UKBB (295,423 individuals)

*

Figure 4.3 Landscape of MultiPhen Results. A position-to-position comparison of
MultiPhen results between eMERGE and UKBB. The red line indicates a p-value of 1´10-8. To
reduce the margin induced by the extreme small p-values, we have collapsed SNPs with p-value
less than 1´10-75 into one overlapping circle indicated by an asterisk on chromosome 4 for UKBB.

We characterized the 607 SNPs that had significant associations with at least one
phenotype in both eMERGE and UKBB via both PheWAS and MultiPhen (Figure 4.2). These
SNPs mapped to 32 genes using the RefSeq database104 in ANNOVAR105 (Appendix A Table S2
and Appendix B Fig. S2A). A total of 204 of these SNP associations met a Bonferroni correction
for multiple testing burden (Appendix B Figure S2B). Pleiotropic effects of these SNPs were
formally tested as reported in the next section. We did not apply any linkage disequilibrium (LD)
filtering on our discovery or replication SNPs in order to capture the SNP-specific characteristics
that could be potentially missed by LD pruning. We wanted to ensure that we could evaluate all
significant SNPs in both eMERGE and UKBB datasets. However, we have provided the LD
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pruned SNPs (r-squared > 0.8) for each genomic region in both datasets (Appendix A Table S2).
We have also provided the regional LD structure for the discovered pleiotropy throughout the next
section.

4.4.3

Formal Test of Pleiotropy

The formal test of pleiotropy was conducted on 607 SNPs using a p-value threshold of 1´108

for a selected set of phenotypes in each of the two datasets, independently. There were 287

SNPs in eMERGE and 331 SNPs in UKBB which indicated statistically significant associations
with at least two phenotypes. Among these, 52 SNPs in eMERGE and 59 SNPs in UKBB showed
associations with both circulatory system diseases and nervous system disorders (Figure 4.4;
details in Appendix A Table S3). We characterized the direction of genetic effect sizes from
PheWAS results (Appendix A Table S7). An illustration of identified pleiotropic relationships
among disease categories is shown in Figure 4.5 (details in Appendix A Table S4). We reviewed
the NHGRI-EBI GWAS catalog18,19 for discovered pleiotropic common SNPs, and their associated
traits relevant to our trait of interest and the direction of genetic effect size are reported in
Appendix A Table S3. We also discussed the number of cases that overlap between traits as well
as the correlation among traits in the Appendix B.
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Figure 4.4 Characterization of Top Associated Diseases for Identified Pleiotropy. The
diseases are characterized by sequential multivariate analyses and the direction of genetic effect
is obtained from PheWAS results. The direction of genetic effect is based on the tested allele in
our study. More details are shown in Appendix B Table S3. Note that the direction of genetic
effect on chromosome 9 is a mixture of risk and protective effects for our tested alleles on two
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We identified 20 SNPs at chromosome 19q13.32 that suggested pleiotropy across
circulatory system diseases and nervous system disorders from UKBB (Appendix A Table S3,
regional LD in Figure 4.6). Those SNPs mapped to a region containing the genes APOC1,
APOC1P1, TOMM40, APOE, and NECTIN2. All 20 SNPs are associated with atherosclerotic
heart disease, Alzheimer’s disease, and dementia, while 14 SNPs are also associated with
angina pectoris and 18 SNPs are associated with delirium (Figure 4.4). This region was found to
be significantly associated with Alzheimer’s disease in previous studies70,71,106. There are 8 SNPs
that have previously demonstrated associations with cardiovascular disease risk factors such as
HDL cholesterol, LDL cholesterol, total cholesterol, and triglycerides107-110. Only one SNP,
rs4420638, has previously been associated with coronary artery disease111 based on our review
of the NHGRI-EBI GWAS catalog18. Our study showed the associations of these SNPs with
circulatory system disease status such as acute transmural myocardial infarction of inferior wall
and occlusion and stenosis of carotid artery. All of the 20 SNPs demonstrated risk pleiotropic
effects across all the identified circulatory system diseases and nervous system disorders, which
is consistent with suggested trait-related associations from previous studies in GWAS catalog
(Appendix A Table S3). Based on the evidence in the literature, the chromosome 19 results are
predominantly positive control associations that confirm previous findings (proof of concept
signals).
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Figure 4.6 Regional LD Relationships among Identified Pleiotropic SNPs on
Chromosome 19 from UKBB. The phenotype in the top plot is Alzheimer’s disease; and the
bottom plot is atherosclerotic heart disease.

There are in total 63 SNPs at chromosome 9p21.3 that demonstrated pleiotropic
associations with a wide range of circulatory system diseases and major depressive affective
disorders from the eMERGE and UKBB (Appendix A Table S3, regional LD in Appendix B Figure
S3A). The SNPs mapped to the CDKN2B antisense RNA 1 region, which has long been known
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as a hot spot that is associated with cardiovascular diseases112. We not only detected previously
known SNPs associated with cardiovascular diseases, such as rs10757278113 and rs1333045114,
but also demonstrated a novel potential pleiotropic effect on major depressive disorders in this
region, which was not observed in the GWAS catalog. 53 of these 63 SNPs were found to have
opposite directions of genetic effect on circulatory system diseases and major depressive
disorders (Appendix A Table S3); an example of discordant pleiotropy. For SNPs previously
known to be associated with circulatory system diseases, the direction of genetic effect sizes was
consistent with previous studies in the GWAS catalog (Appendix A Table S3).
We characterized two regions that have suggested pleiotropy on chromosome 6: 12 SNPs
near the HLA complex region at 6p21.3 in eMERGE and 9 SNPs near the
LOC101929163/NOTCH4 region at 6p21.3 in UKBB (Appendix A Table S3, regional LD in
Appendix B Figure S3B & C). The genetic variants in the HLA region showed novel pleiotropic
associations with atherosclerosis of arteries of extremities, multiple sclerosis, and Parkinson’s
disease (Appendix A Table S3), none of which have been reported in the GWAS catalog (though
there are other SNPs in the HLA region that have previously been associated with multiple
sclerosis115,116). Of note, 10 of the SNPs near the HLA region demonstrated opposite directions of
effect on circulatory system diseases and nervous system diseases (Appendix A Table S3), while
the remaining 2 SNPs showed the same direction of effect (risk effect of tested allele) on
pulmonary embolism and infarction and multiple sclerosis. The 9 SNPs we identified in the
LOC101929163/NOTCH4 region, which are in high LD, have opposite directions of effect on
essential hypertension and multiple sclerosis, which has not been characterized before in the
GWAS catalog.
Finally, we also identified 3 SNPs near PRDM8/FGF5 at chromosome 4q21.21 that are
associated with essential hypertension and severe depressive episode with psychotic symptoms
from UKBB, with risk genetic effect on both diseases (Appendix A Table S3, regional LD in
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Appendix B Figure S3D). All 3 SNPs were suggested in the studies from GWAS catalog to
increase the risk of hypertension or related traits117-122 (positive controls in our study), but we did
not find evidence that they increase the risk of severe depressive disorders in the literature.

4.5

Discussion
Many clinical and epidemiological studies have suggested the co-occurrence of circulatory

system diseases and nervous system disorders. However, the genetic contributions to this
relationship are largely unknown. To bridge this knowledge gap, we have characterized pleiotropy
across these two broad disease categories by applying an effective analytical framework on two
biobank cohorts: eMERGE and UKBB. Even though the prospective UKBB cohort has a large
overall sample size, the case number for specific disease phenotypes is overall comparable to
the medical eMERGE Network in most scenarios (Appendix A Table S1).
One of the advantages of our analytical design is the application of standardized univariate
PheWAS and multi-trait joint analyses on two independent large datasets. As the availability of
summary statistics from the GWAS catalog continues to increase, our ability to compare the
summary statistics from univariate analyses, which is the commonly used approach to
characterize pleiotropy, will continue to grow. However, multivariate methods, which have
demonstrated generally greater power in simulation scenarios78, have not been widely applied to
natural biomedical datasets to study pleiotropy among disease states. The primary reasons are
that most multivariate analyses in general are characterized by the following: 1. Require
individual-level data; 2. Are computationally intensive, and 3. Only test a null hypothesis that a
variant affects none of the phenotypes examined (rather than identifying which subset of
phenotypes are associated). We have addressed these challenges by obtaining individual-level
data, splitting the genotype file into small chunks and running the analyses in parallel, and we
have conducted a formal test of pleiotropy to pinpoint the specific associated phenotypes. We
have applied both univariate PheWAS and multi-trait joint analyses as complementary methods to
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provide supporting evidence for our findings and identify a smaller set of SNPs to explore a
formal statistical test of pleiotropy. Subsequently, there are multivariate methods, such as
MTAG4 or MultiABEL123, that perform multi-trait analysis using GWAS summary statistics in a
more computationally efficient manner. But these methods treat sample overlap as a nuisance
and correct for it, while also being unable to consider scenarios where an individual has multiple
phenotypes diagnosed. This is an additional motivation for using a method, like MultiPhen, that
requires individual level data.
We characterized 607 SNPs that were identified by both PheWAS and MultiPhen methods in
the discovery analyses eMERGE and replicated in UKBB (Appendix A Table S2). These SNPs
were associated with at least one tested phenotype. However, the definition of pleiotropy requires
a genetic variant to influence more than one phenotype. Therefore, we have identified the precise
set of phenotypes associated with a SNP via the sequential multivariate method (a formal test of
pleiotropy). To assist the interpretation of pleiotropy, genetic effect sizes were collected from
univariate PheWAS results. Additionally, the evaluation of the proportion of case overlap and
conditional analyses on each identified phenotype set indicate that our discovered pleiotropy
signals are likely genetic associations rather than due to comorbidity between circulatory system
diseases and nervous system disorders (see Appendix B Supplementary Text).
SNPs that were identified on chromosome 19 were previously known to increase the risk of
Alzheimer’s disease and cardiovascular disease risk factors from GWAS catalog124 (proof of
concept findings). We have identified consistent pleiotropic effects in this region on
cardiovascular disease status such as atherosclerotic heart disease, left ventricular failure,
occlusion and stenosis of carotid artery, and acute transmural myocardial infarction. The
associations with atherosclerotic heart disease, Alzheimer’s disease and dementia were found in
both combined analyses and sex-stratified analyses (see Results and Appendix B Supplementary
Text). The decreased cerebral blood flow due to atherosclerosis is known to be associated with
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pathogenesis of Alzheimer’s disease125. Roher et al. found increased cerebral artery occlusion
and stenosis as a consequence of severe atherosclerotic heart disease in Alzheimer’s disease
from 54 consecutive autopsy cases. Moreover, reducing cardiovascular disease risk offers
opportunities for intervention for Alzheimer’s disease126. Understanding the disease mechanisms
of pleiotropic genes will inform disease treatment.
We observed an association based on SNPs near CDKN2B-AS1, which is associated with
cardiovascular diseases, with the opposite genetic effect on the phenotype of severe depressive
episode without psychotic symptoms. Although we did not identify any significant associations
between CDKN2B-AS1 and major depressive disorders in the GWAS catalog, a recent bivariate
scan study suggested that the genetic variants near CDKN2B-AS1 have the opposite effect on
type 2 diabetes and major depressive disorders127; this confirms our findings. A recent study on
2,743 individuals suggested that coronary artery disease and obesity occur in patients with
depression treated by selective serotonin reuptake inhibitors (SSRIs, antidepressant) 128. The
potential discordant pleiotropic effect of CDKN2B-AS1 might explain the occurrence of coronary
artery diseases in patients treated for depression.
We have identified novel genetic variants near the HLA locus that are associated with
atherosclerosis of arteries of extremities, multiple sclerosis, and Parkinson’s disease, with
opposite genetic effects on the circulatory system and nervous system diseases. Our discovered
SNPs have not been reported before. The HLA gene region, though, has been previously
associated with multiple sclerosis and Parkinson’s disease129,130. Moreover, it has been
recognized that inflammation is involved in atherosclerosis and coronary artery disease131,132,
thus highlighting the possible importance of autoimmune mechanisms and HLA polymorphisms.
The SNPs near the NOTCH4;LOC101929163 region demonstrated association between
essential hypertension and multiple sclerosis, with opposite direction of genetic effect. The
association was also seen in the female-only analyses (see Appendix B Supplementary Text).
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We have not observed associations of our identified SNPs with hypertension or related traits and
multiple sclerosis from the GWAS catalog, although SNP rs9267992 has been suggested to be
associated with multiple sclerosis by one early GWAS study on 978 cases and 883 groupmatched controls130.
The SNPs we report near PRDM8/FGF5 on chromosome 4 showed pleiotropic risk
associations with essential hypertension and severe depressive episode with psychotic
symptoms. While these variants have previously been associated with hypertension or related
traits such as diastolic and systolic blood pressure (per the GWAS catalog), they have not, to our
knowledge, been associated with depressive disorders. Previous epidemiological studies have
consistently shown an increased risk of hypertension in patients with depression and vice
versa133-135. Our observed novel pleiotropic associations might contribute to the explanation of the
relationships between these diseases.
We acknowledge that we only characterized pleiotropic common variants in individuals of
European ancestry due to power considerations, and future research on rare variants as well as
both common and rare variants in other ancestries will shed more light on the shared biology
between these classes of diseases. Another limitation of our analyses is that we only tested a set
of phenotypes for the sequential multivariate model using a univariate p-value ≤ 0.01 in each
dataset, which resulted in different phenotypes tested between datasets and thus the formal test
of pleiotropy was not an exact replication. The reason behind the selection of phenotypes is the
drastically increased computational time as the number of associated phenotypes increases. For
example, SNP rs1333046 that is associated with 20 phenotypes detected by sequential
multivariate model in UKBB costs 587 hours of CPU time. It currently would not be feasible for us
to conduct sequential multivariate analyses for over 100 phenotypes. Future development of
more computationally efficient methods that use individual level data, rather than summary
statistics, would greatly facilitate the detection of pleiotropy.
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We have characterized pleiotropy across circulatory system diseases and nervous system
disorders by applying a combination of univariate, multivariate, and sequential multivariate
methods on eMERGE and UKBB datasets. Our results have provided new insights into the
genetics underlying the relationships between these disease categories, which may assist in
future disease prevention and treatment. Our integrative analytical framework can also be applied
to other disease categories to study pleiotropy comprehensively.
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5.1

Abstract
The development of sequencing techniques and statistical methods provides great

opportunities for identifying the impact of rare genetic variation on complex traits. However, there
is a lack of knowledge on the impact of sample size, case numbers, the balance of cases vs
controls for both burden and dispersion based rare variant association methods. For example,
phenome-wide association studies may have a wide range of case and control sample sizes
across hundreds of diagnoses and traits, and with the application of statistical methods to rare
variants, it is important to understand the strengths and limitations of the analyses. We conducted
a large-scale simulation of randomly selected low-frequency protein-coding regions using twelve
different balanced samples with an equal number of cases and controls as well as twenty-one
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unbalanced sample scenarios. We further explored statistical performance of different minor
allele frequency thresholds and a range of genetic effect sizes. Our simulation results
demonstrate that using an unbalanced study design has an overall higher type I error rate for
both burden and dispersion tests compared with a balanced study design. Regression has an
overall higher type I error with balanced cases and controls, while SKAT has higher type I error
for unbalanced case-control scenarios. We also found that both type I error and power were
driven by the number of cases in addition to the case to control ratio under large control group
scenarios. Based on our power simulations, we observed that a SKAT analysis with case
numbers larger than 200 for unbalanced case-control models yielded over 90% power with
relatively well controlled type I error. To achieve similar power in regression, over 500 cases are
needed. Moreover, SKAT showed higher power to detect associations in unbalanced case-control
scenarios than regression. Our results provide important insights into rare variant association
study designs by providing a landscape of type I error and statistical power for a wide range of
sample sizes. These results can serve as a benchmark for making decisions about study design
for rare variant analyses.

5.2

Introduction
During the last decade, genome-wide association studies (GWAS) have greatly advanced

our understanding of the impact of common variants on complex traits. The associations of alleles
with frequency more than 1-5% have provided important insights into research and clinical
practice136,137. Despite GWAS revealing novel disease associations, limited genetic heritability
has been explained by GWAS results138. Rare alleles, with moderately large genetic effect sizes,
may explain more of the phenotypic variance of complex disease139. Low frequency or rare
variants may have an essential contribution to unexplained missing heritability140,141. The
development of sequencing technologies has increased access to rare variation data for large
sample sizes. However, it is crucial to better understand the statistical power and analytic
limitations of rare variant association approaches.
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Due to the low frequency of rare variants, single locus association tests in traditional GWAS
are underpowered for rare variant association analysis48 unless the casual variants have very
large effect sizes142. To boost power, region-based collapsing or binning approaches have
become a standard for analyzing rare variants48. These methods evaluate the association of the
joint effect of multiple rare variants in a biologically relevant region with the outcome142.
Numerous association methods have been developed48,143-151 and this manuscript focuses
on evaluating two of the most commonly used approaches for gene-based testing, burden and
dispersion, using a simulation approach. Burden tests summarize the cumulative effect of multiple
rare variants into a single genetic score and test the association between this score and
phenotypic groups using regression152. The major assumption of burden tests is that all rare
variants in a group have the same direction and magnitude of effect on the trait153, and violation
of this assumption leads to a loss of power151. Dispersion tests, on the other hand, evaluate the
distribution of genetic effects between cases and controls by applying a score-based variancecomponent test142. The sequence kernel association test (SKAT) is a widely used dispersion
method. It applies a multiple regression model to directly regress the phenotype on genetic
variants in a region, followed by a kernel association test on the regression coefficients143. SKAT
is robust to the magnitude and direction of genetic effects as well as to the presence of neutral
variants, or a small portion of disease variants143,153.
Statistical power for both burden and dispersion tests has been assessed in many simulation
settings48,143,154,155, however, these simulations have focused on an equal (or balanced) number
of cases and controls. In real data scenarios, researchers often have unequal (or unbalanced)
number of cases and controls. With the application of association methods on unbalanced
samples, it is beneficial to acquire the expected type I error and power to guide the study design
for rare variant association tests. For example, for diseases that have a low prevalence in the
population, what number of cases and how many controls are necessary to detect the impact of
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rare variation on the disease? In phenome-wide association studies (PheWAS)34 there are
potentially a wide range of case and control numbers and overall sample sizes across hundreds
of diagnoses and traits32,156,157. A challenge for PheWAS studies using rare variants is to
understand the impact of varying sample sizes, varying case numbers, and genetic effect sizes32.
In this study, we performed extensive simulation analyses to assess the influence of sample
size on the type I error and power distribution for regression (a burden test) and SKAT (a
dispersion test). We designed twelve balanced sample size datasets and twenty-one unbalanced
sample size scenarios. Since a large sample size has been widely known as a necessity for
detecting significant rare variant associations48,152, in this paper, we mainly simulate unbalanced
scenarios using a large total sample size. BioBin51,158,159 was used for rare variant binning and
association testing. Results on the statistical performance of both logistic regression and SKAT
can serve as a benchmark for making decisions about future rare variant association studies.

5.3

Methods
5.3.1

BioBin

BioBin is a C++ command line tool that performs rare variant binning and association testing
via a biological knowledge driven multi-level approach159. The framework of a BioBin analysis is
to group rare variants into “bins” based on user-defined biological features followed by statistical
tests upon each bin. Biological features, which include genes, inter-genic regions, pathways, and
others, are defined by prior knowledge obtained from the Library of Knowledge Integration (LOKI)
database158. LOKI is a local repository which unifies resources from over thirteen public
databases, such as the National Center for Biotechnology dbSNP and gene Entrez database
information185, Kyoto Encyclopedia of Genes and Genomes186, Pharmacogenomics Knowledge
Base187, and others. Several select burden and dispersion-based statistical tests have been
implemented into BioBin51,158, namely linear regression, logistic regression, Wilcoxon rank-sum
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test, and SKAT143, which allows users the option of choosing the appropriate test(s). All of the
statistical tests have been retained as their original statistical testing framework within BioBin.
BioBin also enables users to perform association analysis across multiple phenotypes in a rare
variant PheWAS. In this paper, we evaluate power and type I error using both logistic regression
and SKAT using the BioBin 2.3.0 software158. BioBin software and the user manual are freely
available at Ritchie Lab website (https://ritchielab.org/software/biobin-download).

5.3.2

Simulation Design

Sample Size and Case Control Ratios
Simulations were designed to systematically evaluate the impact of different sample sizes,
as well as different case control ratios for rare variant association tests. Twelve different
scenarios for a balanced number of cases and controls with a total sample size ranging from 20
to 20,000 were simulated. For unbalanced scenarios, a wide range of tests were constructed with
case numbers varying from 10 to 7000 and two sets of large control samples (10k and 30k). Case
to control ratio was calculated as the number of cases divided by the number of controls. Details
of the study design with respect to sample size are shown in Table 5.1. Moreover, we also
designed a few simulations with larger control groups (50k, 100k and 200k), results of which are
shown in Appendix C table S1. Finally, it is important to note that the results would be
comparable even if the scenario is reversed and the data included more cases than controls. As
long as the customized Madsen and Browning weighting scheme is used, then the results would
be the same whether the data include 1000 cases and 100 controls or 100 cases and 1000
controls (Appendix C Fig. S4).
Minor Allele Frequency
Minor allele frequencies (MAFs) were randomly assigned to our simulated rare variants
using allele frequency distribution data from actual whole exome sequencing data from 50,726
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patients from the MyCode Community Health Initiative as a part of the DiscovEHR project160. Due
to the rounding precision of MAF that SeqSIMLA2188 requires, we used 0.0015 as the MAF lower
boundary to avoid zero MAF for simulated variants. For the MAF upper bound (MAF UB), we
simulated two sets of data, one with MAF UB 0.01 and the other with MAF UB 0.05, respectively.
Parameter Settings
As our primary goal is to compare the effect of case-control sample sizes, we set other
parameters as constant across all the datasets (Table 5.2). All simulations were generated with
an average of 143 loci per dataset as we calculated this to be the mean number of rare loci from
800 genes in a recent PheWAS study161. Here, “locus” refers to a genetic location which harbors
genetic variants. We also applied a customized Madsen and Browning146 weighting scheme as
implemented in BioBin for all datasets in order to increase statistical power51.
Simulation model
All of the datasets were generated using the software SeqSIMLA2.8, which can be used to
design simulated datasets given user-specified sample size, effect sizes for genetic traits, and
genetic model188. The disease penetrance model in SeqSIMLA is based on a logistic function188:
logit (P(case)) = α + β1x1 + β2x2 + β3x3 + ... + βpxp
x1, x2, x3, …, xp represent the genotypes across p disease loci. β1, β2, β3, ..., βp represent the
log of the odds ratios. SeqSIMLA will search for α so that the disease prevalence is close to the
specified prevalence. Here, disease prevalence was set to 5%.
Type I Error (T1E) and Power Simulation
Each type I error or power value was calculated from 1000 independent simulated datasets
with significance assessed at a=0.05. We replicated 1000 runs 30 times as to account for
sampling variability. Running 30 replicates of 1000 datasets was optimal to reduce computational
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and memory burden. The simulated data did not have any missingness in either genotype or
phenotype. Type I error was obtained from null datasets with no genetic association signal. For
power, 10 random disease loci with an odds ratio of 2.5 per locus were simulated. In our study,
power is defined as the probability of detecting a true signal (i.e. to reject the null hypothesis)
when the null hypothesis is false. Power is calculated as the number of datasets that have
rejected the null hypothesis at a=0.05 level divided by the total number of datasets (i.e. 1000).
We also designed three sets of mixed odds ratio models where half of the 10 disease loci had
protective effects, and half had risk effects, as described more in the next section.
Table 5.1 Simulation Design

Balanced Cases and Controls
Total Sample Size 20, 50, 100, 200, 400, 1k, 2k, 4k, 6k, 10k, 14k, 20k
Unbalanced Cases and Controls
Number of controls 10k
Number of controls 30k
Number of cases
Number of cases
10, 25, 50, 75, 85, 100, 200, 500, 1000,
10, 25, 50, 75, 85, 100, 200, 500,
3000, 5000, 7000
1000

Table 5.2 Other Parameter Settings

Number of Simulations
Upper Threshold for MAF
Variant Weighting
Disease Prevalence
Number of Disease Loci
Odds Ratio (OR)

1000 * 30 times for each sample size scenario
0.01 and 0.05
Madsen and Browning
5%
10
All disease loci with OR 2.5; Half of disease loci
with risk effect, the other half with protective effect

Mixed Odds ratio models
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For most of the simulations, an odds ratio of 2.5 was used for 10 disease loci, indicating
consistent risk for all associated rare variants. We also designed three types of protective and risk
odds ratio combinations for the 10 disease loci. The detailed odds ratio for 10 disease loci are
shown in Table 5.3, where variants were assigned a range of “Low”, “Moderate”, or “High” risk or
protective impact, randomly. For each mixed model, we calculated protective (OR<1) effect as
the same as the risk effect as to retain the consistent range of association signals.

Table 5.3 Detailed Parameters for Mixture Odds Ratio Design

Randomly Selected 10 Disease loci
OR > 1 range (Risk)
OR < 1 range (Protective)

Signal Level
Low
Moderate
High

2.3
4
9

2.73
5.25
11.5

3.15
6.5
14

3.58
7.75
16.4

4
9
19

0.43
0.25
0.11

0.37
0.19
0.087

0.32
0.15
0.07

0.28
0.13
0.06

0.25
0.11
0.053

Note: The numbers in bold represent the boundaries when selecting the odds ratios.
5.3.3

Boxplot

All of the boxplots were generated using the “geom_boxplot” function within “ggplot2” R
package64. The “reshape2” R package was used for format changing purposes. Each boxplot bar
represents the distribution of type I error or power calculated from 30 replicates.

5.4

Results
We evaluated burden-based tests using logistic regression and dispersion-based tests using

SKAT. All associations are evaluated for a binary outcome on a simulated gene with an average
of 143 rare variant loci. We varied the number of cases, controls, and also the balance between
cases and controls. All reported results here have a MAF upper bound (UB) set at 0.01. The
supplementary material (Appendix C Fig. S1 and Appendix C Fig. S2) shows results with a MAF
upper bound (UB) of 0.05.
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5.4.1

Type I error results
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Figure 5.1 Type I error Simulation Results with MAF UB of 0.01.
For visualization and comparison purposes, blue and red horizontal lines indicate type I error
at 0.05 and 0.1 respectively. Figure (A) shows the results for type I error for an equal number of
cases and controls for differing sample sizes. Note that the y-axis only goes to a type I error rate
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of 0.1. Figure (B) shows the type I error rate for different unbalanced cases and controls as
arranged by case to control ratio. The axis is labeled by the number of cases then the number of
controls for each simulation. The percentage of cases to controls is also listed below the number
of cases and controls. Figures (C and D) show the results as ordered by the number of cases.
Fig. 1C has 10K control and Fig. 1D has 30K control.

Figure 5.1 displays the overall type I error simulation results for both balanced and
unbalanced sample sizes. As shown in Figure 5.1A, with balanced number of cases and controls,
the type I error for both regression and SKAT is well controlled under 0.05 with a few exceptions
(the type I error for these was still below 0.1). Interestingly, regression had an overall higher type I
error rate compared with SKAT for balanced samples. In addition, SKAT had an overall slightly
increased type I error as the overall sample size increased. For regression, however, with
increasing overall sample size, we did not observe an overall increasing trend in the Type I error
rate. Similar results have also been observed with MAF UB of 0.05 (Appendix C Fig. S1A).
For unbalanced sample sizes, we investigated whether the type I error rate was driven by
the ratio of the cases to controls or by the number of cases when having a large control sample.
We ordered the sample sizes by case to control ratio in Figure 5.1B, and by case number within
the same control sample size in Figure 5.1C and Figure 5.1D. The type I error distribution for
differing numbers of cases regardless of the number of controls had similar trends (Figure 5.1C
and Figure 5.1D). Thus, our results suggest that number of cases tends to drive the type I error
rate in addition to the case to control ratio under large control group scenarios.
An overall higher type I error rate in unbalanced case-control ratios (Figure 5.1B) was
observed compared to balanced case-control ratios (Figure 5.1A) for both tests, most of which
are higher than 0.05. Contrary to what was seen in balanced samples, type I error rates for SKAT
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were overall higher than regression. An exception to this for SKAT is seen when the case number
increased substantially such as 5000 and 7000 cases with 10,000 controls. Overall, for SKAT
there is decreasing type I error trend as case number increases (Figure 5.1C and Figure 5.1D).
Regression, on the other hand, has a relatively consistent type I error in the unbalanced case
control ratio tests.

5.4.2

Power results
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Figure 5.2 Power Simulation Results with Cutoff for Evaluated Variation of MAF 0.01.
Figure (A) shows the results when cases and controls are equal in number. Figure (B) shows the
impact of unbalanced cases and controls on power ranked by the case/control ratio. The percent
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case to control ratio is listed below the x-axis. Figures (C and D) show the results for power with
unbalanced cases and controls ordered by case number with 10K controls (C) and 30K controls
(D).

Odds ratio 2.5
For balanced numbers of cases and controls and an odds ratio 2.5 for rare disease loci, the
power distribution is shown in Figure 5.2A. The results indicate that regression has relatively
higher power than SKAT for a sample size less than 1000, while SKAT has higher power given
larger sample sizes (≥4000). For a total sample size less than 2000, both methods have less than
50% power to detect true positive effects. In order to achieve 90% power, a total balanced
sample size of 4000 is needed for SKAT and nearly 14,000 is needed for regression, based on
our power simulation settings.
Importantly, SKAT has an overall higher power for unbalanced cases and controls than
regression (Figure 5.2B). Similar to the type I error distribution, power was also driven by the
number of cases instead of the ratio of cases to controls under large control group scenarios
(Figure 5.2B-D). Notably, overall power was improved whether tested via SKAT or regression
approach with an unbalanced case control ratio compared to the balanced case control ratio
simulations.
The power analyses for unbalanced samples suggest an overall increasing trend as the
number of cases increases. Based on the MAF UB of 0.01 results (Figure 5.2C and 2D), SKAT
power for an unbalanced number of cases with case numbers larger than 200 does yield a mean
power over 90%. For regression with an unbalanced sample size, more than 1000 cases would
yield a mean power of 90% under a 10,000 controls sample size, while case numbers more than
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500 would yield the same power under a 30,000 subject control sample size. The same trend has
been observed for a MAF UB of 0.05 (Appendix C Fig. S2C and Fig. S2D).
Mixture of Genetic Variation Contributing to Risk and Protection for Outcome
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Figure 5.3 Power Comparison of Three Models with Differing Contributions from
Protective and Risk Rare Genetic Variation.
The results are shown for variants contributing low, moderate, or high impact on outcome risk or
protection. Methods describe the range of odds ratios corresponding to the different categories.
(A) Total sample size of 4000 for balanced cases and controls with MAF UB 0.05. (B) Total
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sample size of 4000 for balanced cases and controls with MAF UB 0.01. (C) 200 cases and
10,000 controls with MAF UB 0.05. (D) 200 cases and 10,000 controls with MAF UB 0.01.

The above power simulations were performed on 10 disease loci where rare variants had an
odds ratio 2.5 contributing to risk. In order to better assess the performance of statistical
methods, we designed three sets of models containing variants contributing to both protection
and risk with varied effect sizes for 10 disease loci (see Methods for more details). We compare
four scenarios here: an upper bound on simulated rare variants with a MAF of 0.01 and 0.05; a
balanced sample size with 2000 cases and 2000 controls, and an unbalanced sample size with
200 cases and 10,000 controls. We chose these sample sizes from the results of our previous
simulations as we observed both regression and SKAT to have adequate power and controlled
type I error with these case control numbers.
As shown in Figure 5.3, the power increases as the impact of rare variation on outcome
increases. SKAT outperforms regression in all scenarios, which is expected since the power for
burden tests decrease when both protective and risk effects are present. Comparing a MAF UB of
0.05 (left two plots) and a MAF UB of 0.01(right two plots) indicates that SKAT has higher power
for MAF UB of 0.05 whereas regression has indistinguishable power differences. When
comparing the top two plots of Figure 5.3 with the bottom two plots, we observe higher power for
regression in unbalanced samples with 200 cases and 10k controls compared to 2000 cases and
2000 controls. However, the opposite trend was observed for SKAT.

5.5

Discussion
Previous simulation studies have been conducted to characterize the statistical performance

for burden and dispersion-based approaches using a balanced population of cases and
controls48,143,154,155. However, there are many scenarios where there may not be balanced case
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control data for a study, and it is important to know if this will be impactful as rare variant
association methods evaluate the joint effect of multiple rare variants between case and control
groups. In this study, we sought to evaluate the influence of case control balance on the statistical
performance of logistic regression and SKAT rare variant methods.
We found an overall higher type I error rate for unbalanced samples (mostly above 0.05)
compared with balanced samples (mostly below 0.05) for both tests, suggesting that an unequal
number of cases and controls has a clear statistical impact on type I error for rare variant
association analysis. Previous research has reported that the type I error rate for SKAT is
conservative for smaller sample sizes143. Indeed, our balanced sample size simulations suggest
the same trend. However, SKAT has an inflated type I error for unbalanced samples with cases
less than 200, thus we recommend researchers interpret those results with caution. Interestingly,
regression shows a well-controlled type I error rate for both balanced and unbalanced samples. If
controlling type I error is the priority, logistic regression is a more appropriate method than SKAT
for both balanced and unbalanced scenarios.
Statistical power largely depends on the number of disease loci and the odds ratio. In this
paper, we evaluated both same-direction signal (i.e. 2.5 odds ratio) and mixed odds ratio models
(Table 5.3) on 10 disease loci out of an average of 143 rare variant loci. We assessed the power
distribution across various sample sizes using an odds ratio of 2.5. For balanced samples, given
that both SKAT and regression have an overall controlled type I error, a total sample size less
than 2000 obtains power less than 50% and more than 4000 obtains power higher than 50%. For
unbalanced sample scenarios, SKAT has an overall higher power distribution than regression.
Results show that at least 200 case samples are needed to obtain a power of 90% via SKAT, and
an even larger number of cases are required for the regression approach.
As for models with a range of variants contributing to risk and protection for an outcome, our
results suggest that SKAT has an overall higher power compared with logistic regression. The
94

results are expected since burden tests lose power when variants contribute to a range of risk
and protection for an outcome. Understandably, as the impact of the rare variants on outcome
increases, power increases for all scenarios.
Based on our type I error and power results across various unbalanced sample sizes, a clear
trend exists between these statistics and the number of cases in addition to the case to control
ratio (simulation results of constant case to control ratio are shown in Appendix C Fig. S3). As
many studies ensure the proper case to control ratio, we also recommend that researchers pay
attention to the number of cases in the rare variation association studies to help achieve expected
type I error and power rates. To our knowledge, our work is the first to propose the landscape of
statistics while varying the balance of sample sizes for rare variant association methods.
The likely reason that our simulations present relatively lower power for regression could be
a small proportion of disease loci being simulated. As the number of disease loci increases, we
expect to observe higher power for burden-based approaches. Future work will aim to simulate
various disease loci and odds ratio combinations to provide comprehensive implications on power
assessment.
In this paper, we have presented a simulation study through a wide range of balanced and
unbalanced sample sizes, to fully assess the type I error and power distribution for burden and
dispersion based rare variant association methods. We observe an impact of sample size
imbalance on the statistical performance which can serve as a benchmark for future rare variant
analysis.
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CHAPTER 6 Investigating pleiotropy from whole-exome sequencing data across
circulatory system diseases and nervous system disorders

6.1

Abstract
Clinical and epidemiological studies have indicated substantial inter-relationships between

circulatory system diseases and nervous system disorders. Pleiotropy, which describes a gene or
a genetic variant that affects multiple phenotypes, is one of the genetic contributions that explains
the shared biology across different disease categories. In this study, we investigated the potential
for pleiotropic genes using rare variants from the whole-exome sequencing data in the UK
Biobank. We especially focused on the non-synonymous rare variants including startloss,
stoploss, stopgain, splicing variants, insertions, and deletions. For the definition of the phenotype,
we leveraged data from electronic health records and derived PheCodes for a wide range of
circulatory system diseases and nervous system disorders. We performed rare variant
association tests for each PheCode independently using both CMC (combined multivariate and
collapsing) and SKAT (sequence kernel association test). In total, we identified 143 pleiotropic
genes that associated with at least one circulatory system disease and one nervous system
disorders. Our work presents potential novel biology on pleiotropy by specifically testing for the
association of rare variants in whole exome sequence data from a large-scale biobank.

6.2

Introduction
The brain-heart connection has been observed throughout the history91. Circulatory system

diseases and nervous system disorders often co-occur, which suggests the inter-relationship
between these two types of diseases75,91,126,162,163. For instance, the prevalence of cardiac failure
is two times higher in late-onset Parkinson’s disease patients as compared to the general
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population93. Also, cardiovascular disease pathways are involved in Alzheimer’s disease162.
Understanding the relationship across these two disease categories would benefit disease
prediction, clinical preventive care as well as minimize drug side effects for vulnerable
populations.
A genetic variant or a gene that affects more than one phenotype is defined as pleiotropy.
Pleiotropy has thought to be a common phenomenon for quite some time; recently, the ubiquity of
pleiotropy has begun to be better characterized in the human genome21,94. Most of the pleiotropy
research thus far has been focused on the common genetic variants6,23,62, including a previous
research studied by our group on circulatory system diseases and nervous system disorders from
the Electronic Medical Records and Genomics (eMERGE) network58. However, the role of rare
variants remains largely unknown.
Whole-exome sequencing (WES) data coupled with the electronic health records (EHR)
provides great opportunities for understanding biology as it relates to low frequency genetic
variation161,164. In this study, we investigated pleiotropic genes by leveraging WES data via rare
variant association analyses in the UK Biobank (Figure 6.1). We conducted burden and
dispersion tests using rvtest50 on individuals of European ancestry from the UK Biobank
(N=32,268). Specifically, we used CMC (combined multivariate and collapsing) method for the
burden test and SKAT (sequence kernel association test) for the dispersion test. We curated the
phenotypes using PheCodes165 with case sample size requirement of at least 100 cases per
phenotype to be included in the analysis. In total, we examined 66 circulatory system diseases
and 28 neurological disorders (shown in Appendix E). Our work presents the framework for
characterizing pleiotropy from an EHR-linked biobank across circulatory system diseases and
nervous system disorders. Meanwhile, we demonstrated the comparison of results generated by
burden and dispersion rare variant association tests for identifying pleiotropy.
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Figure 6.1 Overview of Analysis

6.3

Methods
6.3.1

Datasets

The UK Biobank offers deep genotyping and rich phenotyping for approximately 500,000
individuals24. In the current data release for this study, the whole-exome sequencing (WES) data
were available on approximately 50,000 samples. We excluded individuals whose disease
diagnosis codes (ICD-10) were not available. We also dropped related samples based on those
who were closer or equal to 2nd degree relatives; one person from each pair were excluded. Sexmismatches were also excluded. In total, there were 32,268 individuals of European ancestry who
were included in this study. This project is approved under UK Biobank Project ID 32133.

6.3.2

Rare variant selection
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We define rare variants with a minimum allele count of 5 and the maximum allele frequency
of 0.01. The variant annotation was conducted using ANNOVAR166 refGene database (Version
Oct 24, 2019). We focus our analysis on nonsynonymous rare variants, including startloss,
stoploss, stopgain, splicing variants, insertions and deletions.

6.3.3

Phenotype definition

We first obtained the International Classification of Diseases and Related Health Problems
Version 10 (ICD-10) codes from the EHR data provided by the UK Biobank. We then derived the
PheCodes using the R package165. We used a rule of one, which means that any code with a
minimum count of one code occurrence was included. We also selected a case sample size of
100 cases for each phenotype to ensure that we would have enough statistical power for rare
variant association analysis based on previous simulation studies61. In total, we examined 66
circulatory system diseases and 28 neurological disorders (shown in Appendix E).

6.3.4

Rare variant region-based association analysis

We performed CMC and SKAT using rvtest50 on the variants and samples that passed
quality control. Among a total of 28,278 genes in the database, there were 18,285 genes being
tested with at least one rare variant in the UK Biobank. The covariates included for adjustment in
rare variant association models are age, sex and European-specific principal components.

6.4

Results
The results of the overall CMC and SKAT analyses are shown in Figure 6.2 (CMC) and

Figure 6.3 (SKAT), without consideration of pleiotropy. We observed a difference in the overall
results landscape between the two methods, which is likely due to the way that these two
statistical methods work and the assumptions the methods are making. Burden tests (CMC)
summarize the cumulative effect of multiple rare variants into a single genetic score, which has
the best performance when the directions of genetic effects are in the same direction for all
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variants167. Dispersion tests (SKAT), on the other hand, evaluate the distribution of genetic effects
by applying a score-based variance components test. SKAT is robust to the magnitude and the
direction of genetic effects as well as to the presence of neutral variants, or a small portion of
disease variants153.
We evaluated the number of variants per gene for the set of genes with Bonferroni
significant results in the Figure 6.4 (CMC) and Figure 6.5 (SKAT). The goal was to evaluate the
distribution of the number of rare variants driving the rare variant association signals. We
observed that SKAT identified more Bonferroni significant results (1196 genes) than the CMC
method (360 genes). We also observed that a large proportion of the genes that have statistically
significant results include only one rare variant that contributes to the significance of the results;
this is the case for both CMC and SKAT methods.
We identified a total of 143 pleiotropic genes in the UK Biobank after Bonferroni correction
(p-value threshold 2.9 ´ 10-8) that are associated with at least one circulatory system disease and
one neurological disorder using SKAT (without any filtering on the number of variants). Among
these, 30 genes were also statistically significant by the CMC method (results not shown). For
genes that had at least five genetic variants, SKAT identified 59 pleiotropic genes across the two
disease categories. The detailed results for every gene-phenotype pair is shown in Table 6.1.
There were two genes what were also identified as Bonferroni significant and pleiotropic by CMC
method – these are CACTIN and CACTIN-AS1 genes.
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Figure 6.2 Gene-based Manhattan Plot for CMC Method

Figure 6.3 Gene-based Manhattan Plot for SKAT Method
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Figure 6.2 Number of Variants per Gene Distribution for Bonferroni Significant Hits for
CMC Method
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Figure 6.3 Number of Variants per Gene Distribution for Bonferroni Significant Hits for
SKAT Method
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6.5

Discussion
We applied both CMC and SKAT methods, which perform burden and dispersion tests

respectively, to identify pleiotropy across circulatory system diseases and nervous system
disorders using WES from the UK Biobank. Our analytical framework characterized pleiotropic
genes that indicate statistical significance for at least one phenotype from each disease category.
This study demonstrates the importance of considering rare variation in explorations of pleiotropy
in human genetics studies.
There were two pleiotropic genes identified by both CMC and SKAT methods. CACTIN and
CACTIN-AS1 genes show statistically significant association with aphasia and late-effect of
cerebrovascular disease. CACTIN was known to be involved in the regulation of immune
response and is evolutionarily conserved across organisms168. CACTIN acts as a negative
regulator for Toll-like receptors (TLRs) 169. Interestingly, the antisense RNA 1 CACTIN-AS1,
which encodes a non-coding RNA, is also associated with both disease categories. There was no
previous research in the literature that suggests their role on either aphasia or cerebrovascular
disease. These are important association signals to explore in replication studies in independent
datasets since there is limited support from the literature.
Here, we discuss a few of the discovered pleiotropic genes from the SKAT analyses. The
B3GAT2 gene is associated with congestive heart failure, heart valve replaced, and aphasia. The
encoded protein is involved in the synthesis of human natural killer-1 (HNK-1), which implicates
cellular migration and adhesion in the nervous system104. B3GAT2 is overexpressed in Brain170.
The association with heart disease has not been previously reported in the literature. Similarly,
the rare variants in the MYT1L gene are associated with disease of tricuspid valve and multiple
sclerosis. The variants in this gene have been demonstrated to be associated with cognitive
disability and autism disorder104. A recent study suggested that an intron in MYT1L is associated
with a drug called Allopurinol, which has been recognized for its benefits in cardiovascular
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disease171. Therefore, the MYT1L associations are somewhat supported by prior literature,
although the association with these two specific phenotypes is novel. Another example is the
KCNQ4 gene; it has been shown from our study that it is associated with suicide or self-inflicted
injury, suicidal ideation or attempt, orthostatic hypotension, hypertensive chronic kidney disease
and late effects of cerebrovascular disease. The protein encoded by KCNQ4 was suggested to
play a critical role in regulating neuronal excitability172. The KCNQ4 potassium channels are also
found in the heart with a lesser extent as compared to brain173. There are several drugs being
developed around this gene174. This looks like an important gene to pursue in independent
replication studies as well.
As for the comparison between CMC and SKAT, SKAT clearly identified more Bonferroni
significant pleiotropic genes than CMC (Figure 6.2 and 6.3). Interestingly, with or without the
number of filtering based on the number of variants, all of the significant genes identified by CMC
were also identified by SKAT. However, according to a previous simulation study by our group
comparing the power and type I error rates between burden and dispersion tests, it was
suggested that dispersion tests have higher type I error rates than observed in burden tests61.
Thus, it is conceivable that some of the statistically significant results in these SKAT analyses are
false positives. To fully evaluate the associations from this study, future replication analyses on
additional independent large-scale biobanks would be helpful.
In this study of the WES data in the UK Biobank, we investigated the potential for pleiotropy
driven by rare variants grouped together by gene. The goal was to determine whether we
observe evidence of pleiotropy between circulatory system diseases and neurological disorders
when considering only rare variants as most previous pleiotropy literature in human genetics has
focused on common variants. Through our analyses, we identified many genes that show
evidence of pleiotropy; a total of 59 genes were identified as potentially pleiotropic using SKAT.
While these results are certainly interesting, because of the high type I error rate of SKAT61, it is
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critical to follow-up this study with replication in other comparable datasets. We anticipate that
further exploration and consideration of rare variants from WES or whole-genome sequencing will
lead to an improved understanding of the human biological mechanisms driven by pleiotropy.

Table 6.1 SKAT Bonferroni Significant Results with at least Five Variants per Gene

Gene

Gene_Start
_Position

Chr

Num_va
r_per_ge
ne

SKAT
p-value

PheCode

PheCode description

Disease
category

Aphasia/speech_disturbance

Nervous
Nervous

AGPS

2

177392772

10

8.52E-16

292.1

AGPS

2

177392772

10

1.13E-08

335

AGPS

2

177392772

10

7.57E-10

433.8

Multiple_sclerosis
Late_effects_of_cerebrovascu
lar_disease

ANKRD33B

5

10564069

12

1.75E-11

443.1

Raynaud's_syndrome

Nervous

ANKRD33B

5

10564069

12

6.21E-12

342

Hemiplegia

Nervous

AREG

4

74445135

5

6.75E-20

296

Mood_disorders

Nervous

AREG

4

74445135

5

1.01E-29

296.1

Bipolar

Nervous

AREG

4

74445135

5

2.93E-10

428.2

Heart_failure_NOS

Nervous

ARL14EPL

5

116051465

5

3.75E-10

340

Nervous

ARL14EPL

5

116051465

5

1.13E-08

411.9

Migraine
Other_acute_and_subacute_f
orms_of_ischemic_heart_dise
ase

B3GAT2

6

70856678

9

4.33E-09

292.1

Aphasia/speech_disturbance

Nervous

B3GAT2

6

70856678

9

4.00E-11

395.6

Nervous

B3GAT2

6

70856678

9

8.78E-17

428.1

B9D2

19

41354416

7

1.22E-08

345

Heart_valve_replaced
Congestive_heart_failure_(C
HF)_NOS
Epilepsy,_recurrent_seizures,
_convulsions

B9D2

19

41354416

7

2.54E-09

440

Atherosclerosis

Nervous

BRAP

12

111642145

9

4.49E-59

335

Nervous

BRAP

12

111642145

9

2.00E-12

357

Multiple_sclerosis
Inflammatory_and_toxic_neu
ropathy

BRAP

12

111642145

9

5.00E-11

426.31

Right_bundle_branch_block

Nervous

C3AR1

12

8056843

11

1.13E-17

292.4

Nervous

C3AR1

12

8056843

11

5.58E-10

414

Altered_mental_status
Other_forms_of_chronic_hea
rt_disease

CACTIN

19

3610644

12

5.71E-30

292.1

Nervous

CACTIN
CACTINAS1
CACTINAS1

19

3610644

12

4.31E-18

433.8

Aphasia/speech_disturbance
Late_effects_of_cerebrovascu
lar_disease

19

3607246

7

6.56E-09

292

Neurological_disorders

Nervous

19

3607246

7

4.37E-31

292.1

Aphasia/speech_disturbance

Nervous

106

Nervous

Nervous

Nervous
Nervous

Nervous

Nervous

Nervous

CACTINAS1

19

3607246

7

2.53E-14

433.8

Late_effects_of_cerebrovascu
lar_disease

Nervous

CD63

12

55725442

5

2.11E-08

338

Pain

Nervous

CD63

12

55725442

5

1.05E-10

350

Abnormal_movement

Nervous

CD63

12

55725442

5

8.49E-09

427.7

Tachycardia_NOS

Nervous

CD8A

2

86784604

6

1.46E-09

292.4

Nervous

2

86784604

6

1.25E-08

427.1

CD8A

2

86784604

6

1.96E-12

427.11

Altered_mental_status
Paroxysmal_tachycardia,_uns
pecified
Paroxysmal_supraventricular
_tachycardia

CD8A

CDR2

16

730419

9

8.02E-10

338

Pain

Nervous

CDR2

16

730419

9

6.37E-10

427.9

Palpitations

Nervous

CDR2

16

730419

9

3.87E-09

428.2

Heart_failure_NOS

Nervous

CKB

14

103519666

8

1.22E-09

396

Nervous

CKB

14

103519666

8

3.14E-09

401.22

Abnormal_heart_sounds
Hypertensive_chronic_kidney
_disease

CKB

14

103519666

8

4.18E-09

342

Hemiplegia

Nervous

CLDN5

22

19523026

7

2.07E-08

350

Abnormal_movement

Nervous

CLDN5

22

19523026

7

1.67E-10

420

Carditis

Nervous

CLDN5

22

19523026

7

1.25E-16

420.2

Nervous

CLDN5

22

19523026

7

1.45E-08

447

Pericarditis
Other_disorders_of_arteries_
and_arterioles

CNN1

19

11538850

7

2.84E-09

430

Intracranial_hemorrhage

Nervous

CNN1

19

11538850

7

1.71E-12

342

Hemiplegia

Nervous

CPSF7

11

61402647

7

1.75E-08

338

Pain

Nervous

CPSF7

11

61402647

7

8.12E-09

426.3

Bundle_branch_block

Nervous

DDX41

5

177511576

11

8.32E-13

426.2

Atrioventricular_[AV]_block

Nervous

DDX41

5

177511576

11

1.14E-10

342

Nervous

DHX9

1

182839346

5

1.15E-15

433.2

DHX9

1

182839346

5

5.67E-19

433.21

Hemiplegia
Occlusion_of_cerebral_arteri
es
Cerebral_artery_occlusion,_w
ith_cerebral_infarction

DHX9

1

182839346

5

3.45E-10

342

Nervous

DPEP1

16

89613307

15

1.32E-13

357

Hemiplegia
Inflammatory_and_toxic_neu
ropathy

DPEP1

16

89613307

15

6.51E-20

395.6

Heart_valve_replaced

Nervous

DRD3

3

114128651

7

2.10E-08

345.3

Convulsions

Nervous

DRD3

3

114128651

7

4.16E-11

426.31

Right_bundle_branch_block

Nervous

DSCAM

21

40010998

27

9.90E-18

338

Pain

Nervous

DSCAM

21

40010998

27

6.56E-11

458.1

Orthostatic_hypotension

Nervous

DUSP28

2

240560053

7

3.45E-09

335

Multiple_sclerosis

Nervous

DUSP28

2

240560053

7

7.28E-31

338

Pain

Nervous

DUSP28

2

240560053

7

2.14E-10

430

Nervous

DUSP28

2

240560053

7

4.47E-13

443.9

Intracranial_hemorrhage
Peripheral_vascular_disease,_
unspecified

107

Nervous
Nervous

Nervous

Nervous

Nervous
Nervous

Nervous

Nervous

EHD3

2

31234151

8

3.76E-09

357

Inflammatory_and_toxic_neu
ropathy

Nervous

EHD3

2

31234151

8

4.59E-18

440

Atherosclerosis

Nervous

FH

1

241497556

9

3.20E-10

292.1

Nervous

FH

1

241497556

9

1.21E-12

433.8

Aphasia/speech_disturbance
Late_effects_of_cerebrovascu
lar_disease

FH

1

241497556

9

9.45E-10

342

Hemiplegia

Nervous

FRS2

12

69470387

6

3.31E-09

350.2

Nervous

FRS2

12

69470387

6

2.30E-09

447

Abnormality_of_gait
Other_disorders_of_arteries_
and_arterioles

GDF5

20

35433348

8

1.30E-10

296

Mood_disorders

Nervous

GDF5

20

35433348

8

4.00E-11

428.2

Heart_failure_NOS

Nervous

GOLGA8B

15

34525282

10

1.06E-17

338

Pain

Nervous

GOLGA8B

15

34525282

10

1.92E-11

433.31

Nervous

HDHD2

18

47107409

9

7.15E-11

433.21

HDHD2

18

47107409

9

3.95E-15

433.8

Transient_cerebral_ischemia
Cerebral_artery_occlusion,_w
ith_cerebral_infarction
Late_effects_of_cerebrovascu
lar_disease

HDHD2

18

47107409

9

8.85E-13

342

Hemiplegia

Nervous

HOXD11

2

176107279

7

7.67E-11

296

Mood_disorders

Nervous

HOXD11

2

176107279

7

2.41E-15

296.1

Bipolar

Nervous

HOXD11

2

176107279

7

1.13E-16

394.3

Aortic_valve_disease

Nervous

IQCD

12

113195445

10

9.30E-10

345.3

Convulsions

Nervous

IQCD

12

113195445

10

5.95E-10

458.9

Hypotension_NOS

Nervous

ISOC1

5

129094748

7

5.76E-12

292.1

Aphasia/speech_disturbance

Nervous

ISOC1

5

129094748

7

9.95E-09

345.3

Nervous

ISOC1

5

129094748

7

2.57E-09

352

Convulsions
Disorders_of_other_cranial_n
erves

ISOC1

5

129094748

7

5.28E-09

433.3

Cerebral_ischemia

Nervous

JUP

17

41754606

25

4.33E-12

327.3

Sleep_apnea

Nervous

JUP

17

41754606

25

5.98E-09

394.3

Nervous

KCNQ4

1

40783786

11

1.80E-10

401.22

KCNQ4

1

40783786

11

1.21E-11

433.8

Aortic_valve_disease
Hypertensive_chronic_kidney
_disease
Late_effects_of_cerebrovascu
lar_disease

KCNQ4

1

40783786

11

2.66E-16

458.1

Orthostatic_hypotension

Nervous

KCNQ4

1

40783786

11

6.73E-11

297

Nervous

KCNQ4

1

40783786

11

5.22E-11

297.2

LGALS12

11

63506083

8

9.38E-16

334

Suicidal_ideation_or_attempt
Suicide_or_selfinflicted_injury
Degenerative_disease_of_the
_spinal_cord

LGALS12

11

63506083

8

3.68E-12

394.7

Disease_of_tricuspid_valve

Nervous

LGALS12

11

63506083

8

6.18E-15

396

Abnormal_heart_sounds

Nervous

LHX4-AS1

1

180269662

8

4.45E-11

292.1

Nervous

LHX4-AS1

1

180269662

8

1.09E-13

433.8

Aphasia/speech_disturbance
Late_effects_of_cerebrovascu
lar_disease

108

Nervous

Nervous

Nervous
Nervous

Nervous

Nervous
Nervous

Nervous
Nervous

Nervous

LHX4-AS1

1

180269662

8

9.13E-10

442

Other_aneurysm

Nervous

LHX4-AS1

1

180269662

8

2.59E-12

342

Nervous

LOC283335

12

53043188

5

1.27E-08

451

Hemiplegia
Phlebitis_and_thrombophlebit
is

LOC283335

12

53043188

5

5.61E-13

342

Nervous

LOC283335

12

53043188

5

1.55E-09

451.2

Hemiplegia
Phlebitis_and_thrombophlebit
is_of_lower_extremities

MICALL1

22

37906296

24

3.66E-09

296.1

Bipolar

Nervous

MICALL1

22

37906296

24

2.52E-10

394.3

Nervous

MKRN2

3

12557086

11

5.87E-17

334

MKRN2

3

12557086

11

4.75E-18

411.9

MRPL49

11

65122182

5

3.81E-09

345

MRPL49

11

65122182

5

7.78E-09

447

Aortic_valve_disease
Degenerative_disease_of_the
_spinal_cord
Other_acute_and_subacute_f
orms_of_ischemic_heart_dise
ase
Epilepsy,_recurrent_seizures,
_convulsions
Other_disorders_of_arteries_
and_arterioles

MYT1L

2

1789112

10

3.71E-15

335

Multiple_sclerosis

Nervous

MYT1L

2

1789112

10

3.30E-18

394.7

Disease_of_tricuspid_valve

Nervous

NPRL2

3

50347354

7

4.15E-11

342

Nervous

NPRL2

3

50347354

7

2.03E-09

411.9

OR10K2

1

158419927

7

1.48E-20

433.8

Hemiplegia
Other_acute_and_subacute_f
orms_of_ischemic_heart_dise
ase
Late_effects_of_cerebrovascu
lar_disease

OR10K2

1

158419927

7

8.08E-16

342

Hemiplegia

Nervous

PFKFB4

3

48517683

10

2.15E-12

340

Nervous

PFKFB4

3

48517683

10

4.77E-13

433.8

PIGP

21

37065363

7

1.02E-09

357

PIGP

21

37065363

7

5.89E-09

402

Migraine
Late_effects_of_cerebrovascu
lar_disease
Inflammatory_and_toxic_neu
ropathy
Elevated_blood_pressure_rea
ding_without_diagnosis_of_h
ypertension

PPWD1

5

65563238

15

3.64E-13

394.7

Nervous

PPWD1

5

65563238

15

3.59E-11

433.8

Disease_of_tricuspid_valve
Late_effects_of_cerebrovascu
lar_disease

PPWD1

5

65563238

15

1.87E-12

342

Hemiplegia

Nervous

PTHLH

12

27958083

5

1.96E-08

350

Abnormal_movement

Nervous

PTHLH

12

27958083

5

5.38E-10

420

Carditis

Nervous

PTHLH

12

27958083

5

6.22E-13

420.2

Nervous

PTHLH

12

27958083

5

3.06E-09

451.2

Pericarditis
Phlebitis_and_thrombophlebit
is_of_lower_extremities

RAB24

5

177301189

5

4.68E-14

340

Migraine

Nervous

RAB24

5

177301189

5

1.35E-09

428.2

Nervous

RAB24

5

177301189

5

4.41E-12

433.21

RPS19BP1

22

39529092

5

1.46E-14

414

Heart_failure_NOS
Cerebral_artery_occlusion,_w
ith_cerebral_infarction
Other_forms_of_chronic_hea
rt_disease

RPS19BP1

22

39529092

5

1.02E-10

297

Suicidal_ideation_or_attempt

Nervous

109

Nervous

Nervous

Nervous
Nervous
Nervous
Nervous

Nervous
Nervous

Nervous
Nervous
Nervous

Nervous

Nervous

Nervous
Nervous

Suicide_or_selfinflicted_injury

Nervous

Pain

Nervous

Aortic_valve_disease

Nervous

Alcohol-related_disorders
Other_disorders_of_arteries_
and_arterioles
Late_effects_of_cerebrovascu
lar_disease

Nervous

Hemiplegia
Late_effects_of_cerebrovascu
lar_disease

Nervous

Hemiplegia

Nervous

Heart_valve_replaced

Nervous

Atherosclerosis
Other_disorders_of_arteries_
and_arterioles
Suicide_or_selfinflicted_injury

Nervous

Migraine

Nervous

443.1

Raynaud's_syndrome

Nervous

3.45E-16

350.2

Nervous

16

6.76E-11

433.2

Abnormality_of_gait
Occlusion_of_cerebral_arteri
es

98878489

40

1.79E-08

327.3

Sleep_apnea

Nervous

7

98878489

40

5.17E-10

420

Carditis

Nervous

TRRAP

7

98878489

40

1.72E-15

420.2

Nervous

TTLL1

22

43039515

8

1.29E-12

433.8

Pericarditis
Late_effects_of_cerebrovascu
lar_disease

TTLL1

22

43039515

8

1.26E-09

342

Hemiplegia

Nervous

VAT1L

16

77788563

5

2.17E-08

416

Nervous

VAT1L

16

77788563

5

2.11E-09

293

Cardiomegaly
Symptoms_involving_head_a
nd_neck

RPS19BP1

22

39529092

5

6.72E-11

297.2

SERPINE3

13

51341031

8

8.62E-14

338

SERPINE3

13

51341031

8

1.01E-10

394.3

SGCG

13

23180920

8

2.66E-09

317

SGCG

13

23180920

8

4.02E-09

447

SLC30A7

1

100896089

8

1.01E-10

433.8

SLC30A7

1

100896089

8

3.09E-09

342

SNX30

9

112750759

7

9.04E-09

433.8

SNX30

9

112750759

7

7.55E-09

342

THEM5

1

151847100

5

6.71E-10

395.6

THEM5

1

151847100

5

3.33E-09

440

THEM5

1

151847100

5

1.45E-10

447

THEM5

1

151847100

5

7.97E-09

297.2

TMEM127

2

96250207

6

1.29E-08

340

TMEM127

2

96250207

6

2.86E-10

TMEM171

5

73120574

16

TMEM171

5

73120574

TRRAP

7

TRRAP
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Nervous
Nervous

Nervous

Nervous
Nervous

Nervous

Nervous

Nervous

CHAPTER 7 Summary and Future Directions

Pleiotropy is an important concept in understanding relationships among diseases. In this
dissertation, we presented the contribution of pleiotropy that helps to explain the link between
circulatory system diseases and nervous system disorders. We have reviewed the currently
available statistical methods for analysis of pleiotropy (Chapter 1). We have also applied some of
these current statistical methods for characterizing pleiotropy using either common genetic
variants (Chapters 2, 3, and 4) or rare genetic variants (Chapter 6), respectively. Meanwhile, we
also addressed the potential issue of sample size imbalance between cases and controls for
multivariate association methods in association analysis of common variants in Chapter 2 and
burden/dispersion association methods for rare variants in Chapter 5. The discovery of pleiotropy
was achieved by leveraging large-scale electronic health records linked to biobanks, specifically
eMERGE and the UK Biobank. With the growth of EHR-linked biobanks throughout the scientific
community, we expect to see more future work investigating pleiotropy which will improve our
ability to investigate the shared underlying architecture of human complex traits. Beyond the work
presented in this dissertation, there are many opportunities and challenges ahead.
First, analytical methods for common variants continue to expand from traditional popular
univariate association methods to more robust and powerful multivariate association methods.
We anticipate that this trend will continue in the coming years. Because of the limitations facing
multivariate association methods, future work is greatly needed that focuses on computationally
and memory efficient methods to accommodate the large-scale biobank datasets. This would be
incredibly useful especially given the drastically increasing sample sizes that are being
assembled for the biobank resources, such as the UK Biobank (500,000)24, the VA Million
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Veteran Program (825,000)25, and the All of Us Cohort Program (goal 1 million). As for analyzing
a large number of phenotypes, dimensionality reduction approaches to pre-select subsets of
phenotypes would aid in dealing with computational burden. Downstream analyses on common
variants continue to be needed to characterize the functional implication of the specific genetic
variants that show evidence of statistical association. These analyses include but are not limited
to colocalization analysis89, fine-mapping175 and pathway analysis176. In addition to the GWAS
catalog18,19, a pleiotropy database encompassing genetic associations, gene expression in
specific tissues, and pathway analyses would be a very helpful resource.
Next, the development of multivariate association methods for rare variants is in its infancy.
There are a few proposed methods, described in Chapter 1, that aim to perform multivariate
association tests for rare variants based on either burden or dispersion approaches. However, it
is challenging to apply these different methods at this stage due to the inaccessibility of the
source code or software packages to use the tools. We anticipate that this will be a short-lived
limitation as we expect that these software tools will be made available in the near future.
Additional future work on publicly available, powerful multivariate association tools for rare variant
association would be beneficial to the scientific community. As for considering the functional
annotations for rare variants, there have been a variety of strategies proposed in the literature
thus far. For example, Park et al. performed their rare variant association tests using “predicted
loss-of-function or missense variants” and “predicated deleterious missense variants defined
using REVEL score” 49. Similarly, Verma et al. investigated Drugbank genes (so only a subset of
the genome) specifically using loss-of-function rare variants that were filtered by three different
filtering criteria; in their study only 4 genes showed evidence for association by all three
criteria161. In future, we expect to see various ways of selecting/filtering rare variants as well as
perhaps strategies for grouping the rare variants into regions for the association tests to explore
pleiotropy as related to rare variants. Due to the low minor allele frequency of these rare variants,
replicating the results in independent datasets would certainly help with the confidence of the
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discoveries; however, because the variants are rare, sometimes they do not even exist in
independent datasets. In addition, a univariate association analysis using single rare variant
association tests could potentially help to pinpoint the rare variant(s) that drive the signal,
however, this assumes that the sample size is large enough to have the statistical power needed
to identify the association for the single rare variant.
EHR-linked biobanks will likely continue to play an important role in pleiotropy investigation
and identification. One of the challenges that we face in the use of EHRs for extracting
phenotypes is the manner in which we define the phenotype. One possible future direction is to
refine the definition of each disease phenotype. The ICD codes were designed for billing
purposes in health care systems, however, they also tend to provide a view of the disease profile
for patients. Researchers can either use the ICD codes to define phenotypes34, or seek
alternative phenotype definitions or algorithms to derive phenotype. PheCodes165 are one of the
ways to define phenotypes based on ICD codes with the added interpretation of clinical experts
who spent effort to group ICD codes that go together as well as define exclusion codes that
should not be used177. Another recently proposed alternative data-driven approach for defining
phenotypes is to interrogate disease ontology databases to define the disease status (research
ongoing in Ritchie lab). There are also phenotyping algorithms developed by the eMERGE
network and others in the field of informatics that can be accessed at PheKB
(https://www.phekb.org/). These algorithms incorporate ICD codes, biomarker measurements,
medications, electronic health record notes, etc. to define each phenotype. These carefully
designed phenotype algorithms tend to have a high prediction accuracy in comparison to the
actual clinical diagnosis. Due to the complexity involved in creating these algorithms as well as
the time commitment to develop and evaluate them, these types of algorithms are only available
for a small set of phenotypes at this time. Future methodology developments to improve the
efficiency of the development of these phenotype algorithms would greatly benefit the scientific
community.
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Another challenge facing the use of EHRs for phenotyping is the missingness in the EHR.
For instance, the completeness of EHRs depends on a number of factors. First, the duration of a
patient getting their health care from the current healthcare system. Second, knowing how much
of the previous history for the patient is on record within the system or at least transferred
successfully to the current healthcare system from wherever a patient previously received health
care. Third, presence or absence of health insurance in the United States can determine which
clinical procedures, medications, or laboratory tests some patients may receive. This can create
another type of missingness in the EHR. The reality of missing this previous disease information
may reduce the power for the identification of pleiotropy in these types of broad association
studies, like the ones performed in this dissertation. One other aspect of missingness to be aware
of is the potential impact on the statistical methods. Some statistical and machine learning
methods do not allow for any missing data and thus, the amount of missingness should be taken
into consideration. There are approaches to perform phenotype imputation, such as imputing
missingness as a constant value, however, more robust imputation algorithms should be
implemented. Missingness in the EHR and strategies for dealing with it has been discussed
elsewhere178.
An exciting future for pleiotropy is its potential application for clinical and pharmaceutical
fields. The knowledge of pleiotropy could potentially benefit disease prediction. This is especially
useful for concordant pleiotropy, when a genetic variant or a gene has the same direction of
genetic effect on different diseases. In this way, preventive care could be implemented to protect
patients who carry the risk genetic factors for one disease before they develop another disease;
perhaps preventive measures could be taken. From a disease treatment perspective, it is
possible that a gene that associates with one disease also associated with a drug side effect of,
which can be categorized as another disease phenotype. Perhaps the evidence of pleiotropy can
help to explain these side effects and allow for alternative medications to be administered. For
example, tricyclic drugs for treating depression have lethal effects on patients who are vulnerable
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to cardiovascular diseases179. Future pleiotropy work in other ethnic groups would assist in
disease treatment that benefit broader population. Future effort to develop the strategy of taking
pleiotropic effects into clinical practice and drug development would help to minimize side effects
for certain drugs and potentially help with preventive care.
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